Attorney's Docket No. 1033532-000001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
	)	
Maurice Israel et al.	)	Group Art Unit: 1623
	)	
Application No.: 10/051,243	)	Examiner: **MCINTOSH III, TRAVISS C**
	)	
Filed: January 22, 2002	)	Confirmation No.: 8007
	)	
For: METHODS FOR THE PREVENTION AND/OR THE TREATMENT OF GLUTAMATE CYTOTOXICITY	)	
	)	

DECLARATION OF LAURA BOSSI, M.D.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Laura Bossi, M.D., hereby state as follows:

1. Since 2004 I have held the position of Chief Medical Officer of Faust Pharmaceuticals. Faust Pharmaceuticals has an interest in the above captioned patent application.

2. I am a neurologist and have been involved in neurological research and pharmaceutical development for neurological conditions for more than 30 years. I am a member of the American Academy of Neurology.

3. From 1993-1996, I was Vice-President of CNS Projects for SANOFI Recherche, Gentilly/Paris. From 1997 through 1999, I was Vice-President of the CNS Therapeutic Area for SANOFI Recherche, Gentilly/Paris, France with worldwide responsibility for the clinical development of the CNS portfolio. From 2000-2006, I was President, CEO and Founder of PHYSIS S.A.S., a company providing strategic consulting services in the area of biopharmaceuticals. From 2002-2007, I have held the position of President and co-founder of ELISTEM Biopharmaceuticals S.A.S., a biopharmaceutical start-up company focusing on the development of therapeutic proteins and peptides for disease-modifying treatment of neurodegenerative disorders.

4. Copies of my curriculum vitae and bibliography are attached.

5. The following opinions are based upon my personal experience in the field of neurology and pharmacology. I understand that the subject patent application was first filed in 1999 and was filed internationally in 2000 and entered the U.S. as an application in 2002. Accordingly, I understand that the relevant time period for inquiries related to the state of the art at the time the subject patent application was filed is around 1999. Opinions expressed with regard to what would have been known or believed in the relevant time frame are believed to be consistent with the perspective of a person of ordinary skill in the field from 1999 to the present. I have also consulted with another eminent expert in the field who has provided an independent report that is entirely consistent with my opinions (see below).

6. I have read the above captioned patent application, the pending claims, and the remarks of the examiner concerning the rejection of claims 9, 10, and 12 in view of U.S. Patent Number 5,523,322 issued to Blache et al. and Lechner et al., *Wiener Medizinische Wochenschrift*, 136:387-91, 1986. I have reviewed the Blache and Lechner publications.

7. A person of ordinary skill in the field of the subject patent application in the relevant time frame would have been a person who had a doctorate degree in medicine, pharmacy or science (chemistry, biology, pharmacology...) and several years of research experience particularly related to the development of treatments for neurological disorders including Parkinson's disease.

8. Blache et al. describes a method of inhibiting blood platelet aggregation. Blache et al. would not have suggested a method of treating Parkinson's disease to a person of ordinary skill in the field.

9. Lechner et al. report results of a study on an atypical group of patients with a Parkinson's like disorder that appears to involve a vascular risk. The term "Lechner-Ott-Syndrome" is not found in the general literature on Parkinson's disease. Indeed, the cited article seems to stand alone. In my opinion, a person of ordinary skill in the art would not have considered the report by Lechner et al. in choosing a drug for treatment of Parkinson's disease, because the report of Lechner et al. concerns such an atypical group of patients and the observations of Lechner et al. were never repeated. To choose a drug for the treatment of Parkinson's disease on the basis of the Lechner et al. report would have been contrary to the

LB

conventional wisdom in the field in 1999, and today, regarding the causes and consequences of Parkinson's disease.

10. For the reasons outlined below, I believe that a person of ordinary skill in the art from 1999 to the present would not have considered that Parkinson's disease is caused by vascular lesions, that there is significant vascular involvement in Parkinson's disease, or that an increased vascular risk profile is associated with Parkinson's disease. In particular, a person of ordinary skill in the art would not have considered platelet aggregation to be a factor in Parkinson's disease. Therefore, a person of ordinary skill in the art would not have considered any putative effects on platelet aggregation or other vascular effects in choosing an agent for use in a therapeutic composition for the treatment of Parkinson's disease.

11. Prior to 1999 and since, it has been the prevailing view in the art that Parkinson's disease is not a vascular problem but a primary neurodegenerative disorder of unknown cause. *See, e.g.* Marsden, *Lancet*, April 21, 1990, pp. 948-52. Accepted wisdom in the art in the decade preceding the subject patent application was that "*Research into Parkinson's disease in the next decade will centre on improvements in neuroprotective treatment to prevent or slow the rate of progression of the disease; methods of protection against free radical damage; the role of excitatory amino acid antagonists, and specific methods of delivery of such agents to the brain; and early diagnosis for the most effective use of neuroprotective agents.*" *Id.* at 951, 2nd paragraph.

12. As another example, in 1996 Montastruc et al. stated that "*Although levodopa remains the 'gold standard' in the treatment of the disease...several neuroprotective drugs are now in development in experimental research...*" Montastruc et al., *Drugs and Aging*, 9:169-84, 1996 at 169. Poewe et al. indicated that studies in the late 1990's were directed to the "*...development of neuroprotective strategies that would modify the progression of disease..*" Poewe et al., *Ann Neurol.*, 44:S1-S9, 1998 at §1. The neuroprotective agents expected to give results according to Powe et al. were "*...antioxidants including vitamine C, tocopherol and deprenyl, as well as antiglutamate agents including amantadine, dopamine agonists and neuronal growth factors*" *Id.* at S5, §2. A good clinical review that predicted developments in Parkinson's disease from the time the application was filed in 1999 indicated

that "*clinical trials of new drugs with neuroprotective and neurorescue properties are in progress.*" Schapira et al., *British Medical Journal*, 318:311-14, 1999.

13. Thus, throughout the 1990's levodopa therapy remained the treatment of choice for Parkinson's disease and research and development efforts were directed towards neuroprotective agents and novel dopaminergic drugs. The prevailing view did not consider vascular effects or platelet aggregation as a factor to consider in developing a treatment for Parkinson's disorder.

14. In considering the issues raised by the examiner in the subject patent application, I have consulted a colleague, Christopher G. Goetz, a world renowned neurologist and Parkinson's specialist who holds the positions of Professor of Neurological Sciences and Professor of Pharmacology at Rush University Medical Center, Chicago, Illinois, USA. Dr. Goetz is board certified as a neurologist (1981) from the American Board of Psychiatry and Neurology, and an active member of the American Academy of Neurology, the American Neurological Association, the French Neurological Society, and the Movement Disorder Society. He has been an active researcher in the fields of neurology and pharmacology for more than 30 years and has authored or co-authored more than 300 published scientific and medical journal articles.

15. Dr. Goetz prepared an expert report addressing several inquiries that I put to him. I have read his report and his opinions in the matters discussed in his report are entirely consistent with my own. A copy of Dr. Goetz's report is attached and is incorporated by reference herein in its entirety.

16. Dr. Goetz's analysis shows, and I agree, that Parkinson's disease and vascular parkinsonism are two distinct neurological conditions, and Parkinson's disease is not felt to relate to primary vascular pathology. In my opinion, this has been the prevailing view of persons of ordinary skill in the field throughout the time frame from 1999 to the present.

17. Dr. Goetz's analysis shows, and I agree, that in 1999 as in the present, a person of ordinary skill in the art would have recognized that the small body of evidence for vascular involvement in Parkinson's disease suggests only minor involvement and such involvement may be indirect. In the time frame from 1999 to the present, a person of ordinary skill in the

LB

art would have considered that vascular involvement is not a significant part of Parkinson's disease.

18. Dr. Goetz's analysis shows, and I agree, that the evidence does not suggest that Parkinson's disease relates to a higher vascular risk profile. Indeed, the opposite may be the case. Therefore, I believe that a person of ordinary skill in the art in the time frame from 1999 to the present would not have considered vascular risk profile factors as relating to Parkinson's disease or that a diagnosis of Parkinson's disease implied an increased vascular risk.

19. Dr. Goetz's analysis shows, and I agree, that there has been no conclusive evidence that platelet aggregation is a factor in Parkinson's disease. Moreover, because of the atypical nature of the patients in the group reported by Lechner, and the apparent lack of any other reference to a Lechner-Ott syndrome in the literature of the field, it is my opinion that a person of ordinary skill in the art from 1999 to the present would not have looked to the Lechner report for guidance in developing a treatment for Parkinson's disease.

20. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 10/10/07

Laura Bossi, M.D.

Attachments:
CV and Bibliography of Laura Bossi, M.D.
Expert Report Prepared by Christopher G. Goetz, M.D.

RUSH UNIVERSITY
MEDICAL CENTER

Department of Neurological Sciences
1725 West Harrison St., Suite 755, Chicago, IL 60612
Tel: (312) 563-2900 Fax: (312) 563-2024

Section of Movement Disorders
Christopher G. Goetz, M.D. - Director

Harold L. Klawans, M.D. (1937-1998) - Founder

Cynthia L. Comella, M.D.
Melany M. Danehy, M.D.
Jennifer Goldman, M.D.
Katie Kompoliti, M.D.
Kathleen M. Shannon, M.D.
Leo Verhagen, M.D., Ph.D.
Brandon Barton, M.D.

Elizabeth Zauber, M.D.
Bryan A. Bernard, Ph.D.
Peggie Smith, P.A.C.
Marjorie G. Johnson, L.C.S.W., M.F.T.
Luci M. Blasucci, R.N., C.R.C.C.
Georgian Folino, R.N.
Jean A. Jaglin, R.N., C.R.C.C.

Cheryl Murry
Teresa A. Chmura, B.S.
Bernadette Gillard
Alyce Negron
Marilynn Payton
Tracy Waliczek

Christopher G. Goetz, M.D.
United Parkinson Foundation Professor of Neurology

Dr. Laura Bossi
Faust Pharmaceuticals

October 8, 2007

Dear Dr. Bossi,

I have been contacted by you with a request to address issues related to Parkinson's disease, vascular risk factors, evidence of platelet aggregation defects and evidence of prior therapeutic treatments affecting platelet aggregation in Parkinson's disease. It is my understanding that there are patent issues related to an agent with putative effects on platelet aggregation being developed for an indication of treatment for Parkinson's disease. Several questions have been posed to me and the main time frame of reference is 1999-2002.

I am a neurologist and hold the titles of Professor of Neurological Sciences and Professor of Pharmacology at Rush University Medical Center, Chicago, Illinois, USA. I am board certified as a neurologist (1981) from the American Board of Psychiatry and Neurology, and am an active member of the American Academy of Neurology, the American Neurological Association, the French Neurological Society, and the Movement Disorder Society. I serve as the Co-Editor-in-Chief of *Movement Disorders*, the primary international journal dealing with Parkinson's disease. I am the Editor of the major general neurology textbook, *Textbook of Clinical Neurology* (Saunders-Elsevier Publishers) now in its third edition (2007). I am involved in clinical research and have an active clinical practice that specializes in Parkinson's disease and related disorders. In the past, I directed neurological residency training at Rush University and also served on the MKSAP exam writing committee, so I am very aware of standard neurological knowledge and competency expectations for neurologists in the United States. For these reasons, I consider myself qualified to address the issues that have been posed to me. In the interest of disclosure, I have been a paid consultant by Faust to participate in a conference call to discuss a proposed clinical trial in the past, and I will invoice Faust for my time to prepare this document.

Is Parkinson's disease caused by vascular lesions: is there a distinction between Parkinson's disease and vascular parkinsonism? Parkinson's disease is a primary neurodegenerative disease of unknown cause. The primary anatomical lesion involves degeneration of dopaminergic cells that reside in the substantia nigra (midbrain). These cells have projections to the caudate nucleus and putatmen (striatum) and synthesize the neurochemical, dopamine. As such, the hallmarks of Parkinson's disease are: **degeneration** of the substantia nigra dopamine cells and striatal **depletion** of dopamine.[1] Whereas the cause of this degeneration and selective dopaminergic cell loss is unknown, hypotheses have focused on oxidative stress, free radical toxicity, and protein aggregation abnormalities that lead to progressive cell loss and secondary dopamine striatal depletion.[2]

In contrast to Parkinson's disease, patients in the aging population can develop strokes and when the vascular damage occurs in the striatum or surrounding areas, parkinsonism can develop.[3,4] This entity, termed "vascular parkinsonism" is distinct from Parkinson's disease and was clearly recognized in the period of interest (1999-2002).[4] Vascular parkinsonism cases accounted for 3-6% of cases in one clinic series of patients referred for parkinsonism.[3] Other series have higher rates, likely reflecting more specialized tertiary care centers.[4] Among patients being evaluated for deep-seated strokes (lacunar strokes), 38% have signs of parkinsonism.[3] Among subjects with vascular parkinsonism, older age, prominent gait impairment rather than tremor, predominant lower body signs, falls and instability, dementia, signs of pyramidal tract involvement, and poor response to levodopa are typical[4], helping clinicians to distinguish cases from those with Parkinson's disease. Abnormal MR or CT scans showing evidence of strokes, a past history of clinical strokes that precede parkinsonism and vascular risk factors like hypertension, heart disease, diabetes, hyperlipidemia and smoking are significantly more common in vascular parkinsonism than Parkinson's disease.[4] In another study of 60 patients referred for evaluation of Parkinson's disease, 16 (27%) had signs of cerebrovascular disease. Only one patient with typical signs of Parkinson's disease had evidence of vascular disease.[5] This latter observation indicates that on very rare occasions, the differentiation between Parkinson's disease and vascular parkinsonism may be difficult, but in the large proportion of cases, the two syndromes are categorically distinct.[6-8] The distinction is operationalized in the entry criteria for clinical trials of Parkinson's disease and in my experience participating in over 100 treatment protocols for Parkinson's disease patients, subjects with vascular parkinsonism are always excluded, because they are considered to have an entirely separate entity. In summary, Parkinson's disease and vascular parkinsonism are two distinct nosological categories among neurological diagnoses, and Parkinson's disease is not felt to relate to primary vascular pathology.

Is there any evidence for vascular involvement in Parkinson's disease? Whereas strokes causing vascular parkinsonism are altogether different from Parkinson's disease, there is a small body of evidence that implicates at least minor vascular involvement in Parkinson's disease. First, in some reports, hyperhomocysteinemia has been documented in Parkinson's disease patients, although the elevated levels may be related to levodopa treatment as opposed to the disease itself.[9,10] Certain genotypes may be more likely to express hyperhomocysteinemia than others.[11] Additionally, though controversial, some studies suggest that vascular amyloid-beta deposition occurs in Parkinson's disease.[12] These issues are not settled, and their implications in terms of dopamine cellular degeneration, the hallmark of Parkinson's disease, is unknown. The seminal data pertinent to this area of science are all more recent than the period in question (1999-2002).

What is the vascular risk factor profile of patients with Parkinson's disease? Studies of risk factors for Parkinson's disease have consistently documented that a family history of Parkinson's disease, pesticide/herbicide exposure, and well-water drinking increase the risk of disease whereas tobacco use is a protective influence.[13,14] In a study specifically examining risk factors for vascular disorders in Parkinson's disease patients, diabetes, smoking, hypertension, high blood glucose, high cholesterol and triglycerides were significantly less frequent in Parkinson's disease patient compared to controls.[15] As early as 1990, epidemiological studies have documented a lower risk of stroke in patients with Parkinson's disease, and have hypothesized that this effect may be due to less tobacco use, decreases in generalized atheroschlerosis and dopamine deficiency.[16] Whereas, these observations suggest that Parkinson's disease patients are actually protected against strokes, published studies and clinical experience clearly demonstrate that Parkinson's disease can develop stroke as a late co-morbidity. Older age is associated with increased risks of co-morbidities in Parkinson's disease,[17] and when a stroke occurs, overall morbidity is higher compared to patients without added strokes.[18]

Does platelet aggregation occur as part of Parkinson's disease? As a physician who has devoted his academic career to the study and treatment of Parkinson's disease, I am not aware of any large study assessing platelet aggregation abnormalities in Parkinson's disease. In a PUBMED search of

"Parkinson's disease" and "platelet aggregation" there were 15 "hits", but only three articles with any pertinence to the issue. Two of these are in English, and one in German. A 1991 letter to the Editor of *Stroke* reported that a small sample of 25 Parkinson's disease patients were compared to 25 age- and gender-matched controls for platelet aggregation.[19] The authors found that platelet aggregation induced by adenosine diphosphate and epinephrine was significantly decreased in Parkinson's disease subjects, whereas collagen-induced aggregation did not differ between the two groups. They hypothesized that the lower incidence of stroke observed in Parkinson's disease patients may relate in part to this aggregation profile.[19] To my knowledge, this observation has not been replicated in a second or larger sample. A 1976 letter to the Editor of the *British Medical Journal* examined platelet aggregation in PD patients being treated with bromocriptine, a dopamine agonist, and found no drug-related effects on platelet aggregation. Data were not shown, but no indication of aggregation abnormalities prior to bromocriptine were described and bromocriptine did not change platelet aggregation profiles after 15 days of treatment.[20] Finally, the report by Lechner and Bertha described a group of parkinsonian patients with late disease onset, a high prevalence of diabetes mellitus, increased blood viscosity, enhanced platelet aggregation, abnormal electroencephalograms, and poor levodopa response.[21] This clinical profile is atypical for Parkinson's disease because of the poor response to the gold standard treatment for the disease, levodopa. The authors named this syndrome as Lechner-Ott syndrome, an eponym I have never encountered in my career. In checking the index of my own textbook and five other general neurology texts, I do not find this designation listed. A PUBMED search for Lechner-Ott syndrome identifies only the Lechner article cited above. Although I can find no further references to this syndrome, the clinical description of these patients is distinct from Parkinson's disease and warrants a separate designation.

Among current treatments for Parkinson's disease, is anti-platelet aggregation generally used to treat PD?
Since the 1980's, the treatment of Parkinson's disease remains anchored in replacement strategies for the lost dopamine that is the basis for the motor impairments of the disease. Levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors are the primary agents used.[22] I have been a consultant to pharmaceutical firms developing all of these classes of drugs, and in my experience of studying the pharmacological profiles of these agents, I have not seen data that used platelet aggregation as an index of anti-parkinsonian efficacy. In the laboratory, drugs with putative effects on Parkinson's disease are screened by their effects on animal models directly related to dopamine depletion. As a teacher and researcher, in 1999-2002, as today, I have never advised or heard other international colleagues discuss anti-platelet aggregation strategies for the treatment of Parkinson's disease.

In this context, however, data from 2007 raise the issue of whether cholesterol sub-types and statin exposure may be related to Parkinson's disease risk. These data represent very early observations that need to be confirmed, but are pertinent to the issue of platelet aggregation. In one report, lower low-density lipoprotein cholesterol levels were associated with a higher occurrence of Parkinson's disease.[23] Further, cholesterol-lowering drugs or statins were associated with a lower occurrence of PD. A second study documented that statin effects may be drug-selective and not cross the entire class of agents, with chronic simvastatin and atorvastatin use associated with a reduced incidence of Parkinson's disease.[24] The biochemistry of statin drugs is complex, and includes stabilization of atherosclerotic plaques, decreased carotid intimal-medial thickness, protective effects agains nitric oxide synthase, anti-inflammatory effects, and possible regulation of dopamine receptors.[25,26] There is however some evidence that these agents may affect platelet function as well, and both lovastatin and fluvastatin have been shown to reduce platelet aggregation.[27] Therefore, if the epidemiological observations are replicated and statin use is truly associated with a lower risk of Parkinson's disease, it is reasonable to consider that one possible mechanism is decreased platelet aggregation. These data examine risk for Parkinson's disease and not therapy for Parkinson's disease, but, in my view, the two issues may potentially be linked and therefore therapeutically relevant. I emphasize the preliminary nature of these data and the inability to make sound conclusions regarding platelet aggregation strategies relative to Parkinson's disease at the present time.

Is the structure of the compound described by Blache et al (US Patent number 5,523,322) similar to that of drugs used to treat Parkinson's disease? I am not a structural chemist, but as a Professor of Pharamcology, I have examined the structure of the compound in the Blache et al patent application and do not recognize similarities to any agent used for treating Parkinson's disease in 1999 or since then.

During the period 1999-2002, would a "person of ordinary skill", defined as a person with a doctorate degree in medicine or science and several years of research experience particularly related to the development of treatments for Parkinson's disease, have considered drugs with effects on platelet aggregation to have a therapeutic role in Parkinson's disease patients?
In the period of 1999-2002, I was Professor of Neurological Sciences and Professor Pharmacology at Rush University Medical Center. As an active teacher, researcher and member of the Movement Disorder Society, the American Neurological Association and the American Academy of Neurology, I was very well aware of the standard knowledge base of the group of colleagues you term "persons of ordinary skill". As an active member of that group, during the period 1999-2002, I can comfortably attest that "persons of ordinary skill" did not consider platelet aggregation disorders to be a factor in the causation or progressive disability of Parkinson's disease. At that time, and since then, "persons of ordinary skill" did not select agents for treating Parkinson's disease based on primary anti-platelet action.

Conclusions:

- Parkinson's disease and vascular parkinsonism are different diagnoses.
- Parkinson's disease patients have a low risk for stroke, but late strokes can occur, especially in old patients. When strokes superimpose on Parkinson's disease, patients endure increased morbidity.
- In Parkinson's disease, there is a small set of data that raise the possibility of vascular involvement (hyperhomocysteinemia and increased vascular amyloid-beta deposition), but typical risk factors for vascular disease are less often seen in Parkinson's disease patients than the general population.
- No large studies demonstrate platelet aggregation alterations in Parkinson's disease. One small study suggested that Parkinson's disease patients have reduced platelet aggregation.
- The Lechner-Ott syndrome is clinically distinct from Parkinson's disease because of its lack of levodopa responsivity. Though the authors described increased platelet aggregation, they designated a special eponym for this distinct group of patients. The Lechner-Ott syndrome is not a regularly recognized term within the standard neurological nosology.
- Treatment for Parkinson's disease is anchored in dopaminergic pharmacology and no agent with a primary activity on platelet aggregation has been developed for Parkinson's disease.
- In 1999-2002, "persons of ordinary skill" (defined above) did not consider anti-platelet aggregation drugs as treatment for parkinsonism in Parkinson's disease. Furthermore, at that time, and since then, "persons of ordinary skill" have not selected agents for treating Parkinson's disease based on primary anti-platelet action.

Sincerely,



Christopher G. Goetz, M.D.
Professor of Neurological Sciences
Professor of Pharmacology

References

1. Goetz CG. Parkinson's disease. *Medlink* www.medlink.com 2006.

2. Litvan I, Chesselet MF, Gasser T et al. The etiopathogenesis of Parkinson's disease and suggestions for future research. *J Neuropathol Exp Neurol* 2007;66:329-336.

3. Foltynie T, Barker R, Brayne C. Vascular parkinsonism: a review of the precision and frequency of the diagnosis. *Neuroepidemiology* 2002;21:1-7.

4. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. *Arch Neurol 1999*;56:98-102.

5. Horner S, Niederkorn K, Ni XS et al. Evaluation of vascular risk factors in patients with Parkinson syndrome. *Nervenarzt* 1997;68:967-971.

6. Thanvi B, Lo N, Robinson T. Vascular parkinsonism: an important cause of Parkinsonism in older people. *Age Ageing* 2005;34:114-119.

7. Rampello L, Alvanao A, Battaglia G et al. Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism. *J Neurol* 2005;252:1045-1049.

8. Sibon I, Tison F. Vascular parkinsonism. *Curr Opin Neurol* 2004;17:49-54.

9. Muller T, Woitalla D, Fowler B et al. 3-OMD and homoscysteine plasma levels in parkinsonian patients. *J Neural Transm* 2002;109:175-179.

10. Rogers JD, Sanchez-Saffon A, Frol AB et al. Elevated plasma homocysteine levels in patients treated with levodopa. *Arch Neurol 2003;*60:59-64.

11. Yasui K, Kowa H, Nakaso K, et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. *Neurology* 2000;55:437-440.

12. Mastaglia FL, Johnsen RD, Byrnes ML et al. Prevalance of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. *Mov Disord* 2003:18:81-86.

13. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? *Adv Neuro l*2003;91:133-142.

14. Dick FD, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. *Occup Environ Med* 2007;64:666-672.

15. Scigliano G, Musicco M, Soliveri P et al. Reduced risk factors fro vascular disorders in Parkinson's disease patients: a case-control study. *Stroke* 2006;37:1184-1188.

16. Struck LK, Rodnitzky RL, Dobson JK. Stroke and its modification in Parkinson's disease. *Stroke* 1990;21:1395-1399.

17. Martignoni E, Godi L, Citterio A et al. Comorbid disorders and hospitalisation in Parkinson's disease: a prospective study. *J Neurol Sci* 2004;25:66-71.

18. Papapetropoulos S, Ellul J, Argyriou AA et al. The effect of vascular disease on late onset Parkinson's disease. *Eur J Neurol* 2004;11:231-235.

19. Sharma P, Nag D, Atam V, et al. Platelet aggregation in patients with Parkinson's disease. *Stroke* 1991;22:1607-1608.

20. Conrad J, Samara M, Bousser MG, et al. Platelet and coagulation studies in patients treated with bromocriptine. *Br Med J* 1976;2:529-30 (letter).

21. Lechner H, Bertha G. Parkinsonism with a high vascular risk—Lechner-Ott syndrome. *Wien Med Wochenschr* 1986;136:387-391.

22. Schapira AH. Treatment options in the modern management of Parkinson's disease. *Arch Neurol* 2007;64:1083-1088.

23. Huang X, Chen H, Miller WC et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. *Mov Disord* 2007;22:377-381.

24. Wolozin B, Wang SW, Li NC et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. *BMC Med* 2007;5:20.

25. Wang Q, Wang PH, McLachlan C et al. Simvatatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-OH dopamine induced parkinsonian rats. *Brain Res* 2005;1045:229-233.

26. Cucciara B, Kasner SE. Use of statins in CNS disorders. *J Neurol Sci* 2001;187:81-89.

27. Aviram M, Hussein O, Rosenblat M et al. Interactions of platelets, macrophases and lipoproteins in hypercholesterolemia. *J Cardovasc Pharmacol* 1998;31:39-45.

CURRICULUM VITAE

Laura BOSSI, MD, Neurologist

Address (office):
Chief Medical Officer,
Faust Pharmaceuticals SA
Bioparc, Bd Sébastien Brant, 67400 ILLKIRCH (Strasbourg), France
Tel (office): 33-(0)3 90 40 61 60
Fax (office): 33-(0)3 90 40 61 65
E-mail: lbossi@faustpharma.com
www.faustpharma.com

Languages: English, French, German, Italian (fluent - speaking, reading, writing); Spanish (speaking, reading)

EDUCATION

1975-1979	Specialization in Neurology, Università degli Studi, Milan, Italy
1977-1978	Hospital Internship, Department of Neuropaediatrics, Neurological Institute C. Besta, Milan
1974-1977	Specialization in Pharmacological Research, Mario Negri Institute, Milan
1969-1975	Medical School, Università degli Studi, Milan
1956-1969	Primary and High School, German School, Milan

DEGREES AND CERTIFICATIONS

1979	Specialist in Neurology (cum laude), Milan University Thesis: Possible role of the serotoninergic system in the pathogenesis of myoclonus.
1977	Specialist in Pharmacological Research, Istituto Mario Negri, Milan
1976	E.C.F.M.G. Certificate (Educational Commission for Foreign Medical Graduates, USA)
1975	Medical Degree (cum laude), Milan University Thesis: Treatment of epilepsy in childhood - results of two years of pharmacological and clinical monitoring.
1969	Abitur (Naturwissenschaftlicher Zweig), German School, Milan Maturità Scientifica, Liceo Vittorio Veneto, Milan

COMPLEMENTARY TRAINING

1994	La gestion chez SANOFI Recherche (residential training in finance and accounting)
1992	Management Center Europe: The Management Forum - Europe 2000 (Berlin)
1991	Management Center Europe: Advanced fundamentals of finance (Brussels)
1990	SDA Bocconi, Milan: Corso interno di formazione dei dirigenti FIDIA (residential advanced management training, Arcugnano, 1 month)
1988	Crown Eagle communication: Licensing (London)

1988 Management Center Europe: Marketing through distributors (Brussels)
1987 Management Center Europe: Fundamentals of finance and accounting for non-financial managers (Paris)

PROFESSIONAL SOCIETIES

American Academy of Neurology
Italian Neurology Society
French Neuroscience Society
International Society for Biological Psychiatry
International Society for the History of Neurosciences

Founding member of the French Foundation for Biological Psychiatry "Fondation Pierre Deniker"

AWARDS

1985 XVI Epilepsy International Symposium, Hamburg, 1984 Clinical Pharmacology Award
1979 XI Epilepsy International Symposium, Florence, Award for Research on Epilepsy

POSITIONS IN THE PHARMACEUTICAL INDUSTRY

Since 5/2004 Chief Medical Officer of FAUST Pharmaceuticals, a clinical stage biopharmaceutical Company focusing on the discovery and development of new therapies for CNS disorders and a spin-off of France's largest research institution, the CNRS (see www.faustpharma.com)

Since 4/2002 President and co-founder of ELISTEM Biopharmaceuticals S.A.S., a biopharmaceutical start-up Company focusing on the development of therapeutic proteins and peptides for disease-modifying treatment of neurodegenerative disorders. Main scientific founder: Alain Prochiantz, director of the department of Biology of the École Normale Supérieure, Paris

2000-2006 President, CEO and Founder of PHYSIS S.A.S., a company providing strategic consulting services in the area of biopharmaceuticals (main clients SANOFI-SYNTHELABO Group, UCB Pharma Corporate, Servier , Associés en Conseil, Tenec, Paris Biotech, biotech and biopharmaceutical start-up companies, Venture Capital societies).

1997- 12/1999 Vice-President, CNS Therapeutic Area, SANOFI Recherche, Gentilly/Paris, France.
Worldwide responsibility for the clinical development of the CNS portfolio (phases IIa-IIIb).
Clinical programs on 10 compounds:
Phase IIIb: Depakine® - Depakote® (mania), Tiagabine® (epilepsy)
Phase III: Xaliprodene, a non-peptidic neurotrophic compound (ALS)

Phase IIb: rimonibant, a cannabis CB1 antagonist in obesity/eating disorders; a 5HT2 antagonist in sleep disorders

Phase IIa: five compounds in schizophrenia (a 5-HT2 antagonist, a sigma ligand, a neurotensin antagonist, a cannabis CB1 antagonist, a neurokinin 3 antagonist); four compounds in major depressive disorders (a beta-3 agonist, a 5-HT2 antagonist, a neurokinin 3 antagonist and a neurokinin 2 antagonist); a non-peptidic neurotrophic compound in dementia (Alzheimer)

Exploratory programs: anxiety disorders, substance abuse, movement disorders, pharmaco-EEG, brain imaging.

Preparation of a NDA (neurotrophic compound – xaliprodene - in ALS).

Number of clinical studies conducted in 1999: 38 trials on 8 compounds; 26 new studies launched.

Direct management of a team of 8 Clinical Research Directors, 6 MDs and 2 PhDs, based in France (5) and in the US (3). Management of an operational team (France-US) of ca 40 people. Coordination of clinical research & operations in the CNS therapeutic area (corporate & clinical research units in the affiliates – ca 200 people). Coordination of subcontracting to various international CROs.

1993-1996 Vice-President, CNS Projects, SANOFI Recherche, Gentilly/Paris

Reporting directly to Gérard Le Fur. Responsible for the preclinical, industrial, regulatory, clinical & strategic marketing development (worldwide) of 14 compounds in the areas of schizophrenia, mood disorders (MDD, bipolar disorders), anxiety disorders, epilepsy, ALS, dementia, sleep disorders, substance abuse, eating disorders, movement disorders.

Coordination of 14 project teams, each including ca 20 specialists (European & US) of all professional areas from preclinical research to marketing.

INDs obtained for 6 compounds.

1989-1991 President and General Manager, Fidia Farmacéutica, Madrid, Spain

Incorporation, organization and management of the Spanish subsidiary of Fidia.

Main missions: to represent the headquarters in the contacts with regulatory authorities in Spain and Portugal, licensees, and production facilities; clinical research in Spain and Portugal, directly or via CROs; harmonization of marketing strategy of licensees; institutional communication

1986-1993 President and General Manager, Fidia France, Paris

Incorporation, organization and management of the French subsidiary of Fidia.

Main missions: preclinical and clinical development, regulatory affairs, out-licensing, marketing strategy (in collaboration with licensees), institutional communication.

Clinical Development (5 compounds) & Regulatory Affairs in the areas of peripheral neuropathies, dementia, stroke, spinal cord injury, osteoarthritis, ocular surgery (European French Speaking Countries, UK, Spain and Portugal).

Marketing approval obtained for Hyal® - Ialum® in ocular surgery (Luxemburg 1991, France 1992, Belgium 1992) and Hyalgan® in osteoarthritis (France 1991, Luxemburg 1992, Belgium 1993).

Preclinical research in the area of neuroplasticity in collaboration with academic research laboratories.

1982-1986 Associated Head, then (1984) Head of the CNS group, Clinical Research Department, LERS (Laboratoires d'Études et de Recherches Synthélabo), Paris
Worldwide clinical development of the CNS portfolio - in the areas of epilepsy, movement disorders, depression, sleep disorders, stroke (phases I-III)
Main projects: Progabide (Gabrene®), Zolpidem (Stilnox®), alpidem, ifenprodil (Vadilex®) and back-up compounds
Marketing approval obtained for Progabide (Gabrene®) in epilepsy (France, 1985)
Preclinical and clinical research collaborations on the role of the GABA-ergic system in epilepsy, mood disorders, movement disorders.

1979-1982 Project leader, CNS international projects, Clinical Research Department, LERS-Synthélabo, Paris, France
Responsible for the clinical development of the CNS portfolio in all countries except France.
Main project: Progabide.
Preclinical and clinical research collaborations on the role of the GABA-ergic system in epilepsy, mood disorders and movement disorders.

RESEARCH POSITIONS

1979-1982 Research Associate, Epilepsy Research Unit 97, INSERM, Paris, France (Dr. Bancaud, Dr. Tailarach)
Semiology of epileptic seizures and localization of the epileptogenic area.
Brain concentrations of anticonvulsants, GABA, and other neurotransmitters in epileptic patients undergoing brain surgery (cortectomy).

1977-1978 Research Associate, Clinical Pharmacology Laboratory, Mario Negri Institute, Milan, Italy (Prof. Garattini, Dr. Morselli)
Clinical pharmacology and pharmacokinetics of antiepileptic drugs. Role of the serotonergic system in myoclonus.
Coordination of a collaborative program (Milan - Berlin, Prof. Janz) on epilepsy, pregnancy, and the child.

1976-1977 Fellow, Research Training Program of the Italian National Research Council (CNR), Mario Negri Institute, Milan, Italy (Prof. Garattini)
Clinical pharmacology of antiepileptic drugs.

BOOKS

1. Epilepsy, pregnancy and the child.
   Edited by D. Janz, L. Bossi, M. Dam, H. Helge, A. Richens and D. Schmidt.
   Raven Press, New York, 1982.

2. Epilepsy and GABA Receptor Agonists, Basic and Therapeutic Research.
   L.E.R.S. Monograph series: Volume 3.

Edited by G. Bartholini, L. Bossi, K.G. Lloyd and P.L. Morselli.
Raven Press, New York, 1985.

3. Histoire naturelle de l'âme.
Laura Bossi
Presses Universities de France, Paris, 2003

4. Scoria naturale dell'anima.
Laura Bossi
Baldini e Castoldi, Milano, 2004

5. Historia natural del alma
Laura Bossi
Antonio Machado Libros, Madrid, 2007 (in press)

BOOKS/TRANSLATIONS

1. Il naso di Giacometti.
Jean Clair.
Translation Laura Bossi.
Donzelli, Roma, 1994

EXHIBITS

1. « Les Siècles d'Or de la Médecine »
Paris - Muséum d'Histoire Naturelle
24 May-18 December 1989 (producer)
Catalogue: Electa, Milan 1989; curator: Yves Hersant

The exhibit was followed by a series of conferences on the history of anatomy.

2. « Ramon y Cajal »
Madrid, Colegio de Medicos
1990 (producer, president of the scientific committee)

The exhibit was followed by an International Symposium, « Santiago Ramon y Cajal – past, present and future », and a series of conferences on the interaction between the neurosciences and creative art work, « El cerebro et si mismo », chaired by L. Bossi and A. Portera-Sanchez

3. « La Fabrique de la Pensée - La découverte du cerveau de l'art de la mémoire aux neurosciences »
Paris - Cité des Sciences, La Villette
18 April 1990 - 6 January 1991
(Producer, member of scientific committee)
Catalogue: Electa, Milano 1990; curator: Pietro Corsi

The exhibit was followed by a series of conferences on the neurosciences.

4. « El Cerebro - del arte de la memoria a la neurociencia »
Madrid - Museo Nacional de Ciencias Naturales, Madrid
14 November 1991-28 February 28 1992
(Producer, member of scientific committee)

5. « L'âme au corps »
Paris - Grand Palais
19 October 1993 - February 1993
(Author of an article published in the catalogue : L. BOSSI, L'âme électrique)
Catalogue: Gallimard – Editions des Musées de France, Paris 1993
Curator: Jean Clair

6. « Chimères »
Montecarlo, summer 2003
(Author of an article published in the catalogue: L. BOSSI, Les chimères existent-elles?)
Curator: Didier Ottinger

7. « Mélancolie. Génie et folie en Occident »
Paris, Grand Palais, 10 October 2005 – 16 January 2006
(Author of an article published in the catalogue: L. BOSSI, Mélancolie et dégénérescence)
Catalogue: Gallimard – Editions de la Réunion des Musées Nationaux, Paris 2005
Curator & editor: Jean Clair

8. « Melancholie. Genie und Wahnsinn in der Kunst ».
Berlin, Neue Nationalgalerie, 17 February – 7 May 2006
(Author of an article published in the catalogue: L. BOSSI, Melancholie und Entartung)
Catalogue: Hatje Cantz Verlag, Ostfildern-Ruit - Editions de la Réunion des Musées Nationaux, Paris, 2006
Curator & editor: Jean Clair

PAPERS

Author of ca 100 full papers and numerous abstracts on neuropsychopharmacology, epileptology, therapeutics, and the history of neurosciences.
The full list of publications is available upon request.

LAURA BOSSI - Bibliography

FULL PAPERS
(in journals and books)

1975

1. BARUZZI A., **BOSSI L.**, CASTELLI D., GERNA M., RIGHETTI A., MORSELLI P.L.
   Alcune considerazioni sulla farmacocinetica dei farmaci anticonvulsivanti nell'età evolutiva.
   Gaslini 7 : 125-130, 1975

2. FARGHALI-HASSAN, **BOSSI L.**, ASSAEL B.M., MORSELLI P.L.
   Placental transfer of carbamazepine in the rat.
   J. Pharm. Pharmacol. 27 : 956-957, 1975

3. VIANI F., **BOSSI L.**, GERNA M., MORSELLI P.L.
   Indicazioni del monitoraggio dei livelli plasmatici dei farmaci antiepilettici.
   Gaslini 7 : 121-124, 1975

1976

4. AVANZINI G., FRANCESCHETTI S., BARUZZI A., BORDO B., **BOSSI L.**, MORSELLI P.L., PORRO M.G., ZAGNONI P., CANGER R., PRUNERI C., VIANI F. (Gruppo Milanese per lo studio delle Epilessie)
   Problemi terapeutici nell'epilessia con crisi parziali : considerazioni su una esperienza di monitoraggio a lungo termine clinico-farmacologico.
   Lega Italiana contro l'Epilessia. Bollettino 15/16 : 37-45, 1976

5. BARUZZI A., BORDO B., **BOSSI L.**, CASTELLI D., GERNA M., PORRO M.G., RIGHETTI A., SOFFIENTINI M.E., ZAGNONI P., MORSELLI P. L., AVANZINI G., BRESCHI F., FRANCESCHETTI S., CANGER R., DE CASTRO R., PRUNERI C., PIGNATELLI G., SMIRNE R., VIANI F. (Gruppo Milanese per lo studio delle Epilessie)
   Monitoraggio intensivo dei farmaci antiepilettici : risultati generali di un'osservazione durata due anni.
   Lega Italiana contro l'Epilessia, Bolletino 15/16 : 27-36, 1976

6. BARUZZI A., **BOSSI L.**, MORSELLI P.L.
   Concentrazioni plasmatiche di di-n-propilacetato e clonazepam nei pazienti epilettici.
   In : Atti des Convegno della Società Italiana di Neuropsichiatria Infantile**. Le epilepssie miocloniche in età evolutiva**, Giovanardi Rossi P., ed., Bologna, pp. 49-62, 1976

7. **BOSSI L.**, BARUZZI A., PORRO M.G.
   Terapia antiepilettica in gravidanza : valutazione rischi-benefici.
   Lega Italiana contro l'Epilessia, Bollettino 15/16 : 89-104, 1976

8. FARGHALI-HASSAN, ASSAEL B.M., **BOSSI L.**, GARATTINI S., GERNA M., GOMENI R., MORSELLI P.L.
Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects.
Arch. Int. Pharmacodyn. Ther. 220 : 125-139, 1976

9. MORSELLI P. L., **BOSSI L.**, GERNA M.
Pharmacokinetic studies with carbamazepine in epileptic patients.
In **: Epileptic seizures, behaviour and pain**. Birkmayer W., Ed., Hans Huber Publi., Berne, Stuttgart. Vienna, pp. 141-150, 1976

10. PAZZAGLIA P., AMBROSETTO G., FORTI A., SACQUEGNA T., LUGARESI E., BARUZZI A., **BOSSI L.**, PORRO M.G., ZAGNONI P.
Il trattamento delle crisi epilettiche parziali con il phenobarbital, la difenilidantoina e la carbamazepina : studio longitudinale (4-22 mesi) guidato dalla determinazione dei livelli plasmatici.
Lega Italiana contro l'Epilessia, Bollettino 15/16 : 55-64, 1976

11. TOGNONI G., BARUZZI A., **BOSSI L.**, ZAGNONI P.
Sperimentazione clinica o critica della pratica medica ?
In : **Atti des simposio della Società Italiana di Neuropsicofarmacologica**, A. Marino e D. de Maio e D. de Maio, Eds., Anacapri, Giugno 1976, pp. 61-69

12. VIANI F., RIBOLDI A., ROSSOTTI V., BARUZZI A., **BOSSI L.**, CASTELLI D., MORSELLI P. L., SOFFIENTINI M.E., ZAGNONI P., AVANZINI G., FRANCESCHETTI S., CANGER R. (Gruppo Milanese per lo studio delle Epilessie)
Monitoraggio a lungo termine dei farmaci antiepilettici : risultati in pazienti con sindrome di Lennox-Gastaut
Lega Italiana contro l'Epilessia, Bollettino 15/16 : 47-54, 1976

1977

13. AVANZINI G., BARUZZI A., BORDO B., **BOSSI L.**, BRESCHI F., CANGER R., DE CASTRO R., FRANCESCHETTI S., GERNA M., MORSELLI P. L., PIGNATELLI G., PRUNERI C., SMIRNE S., VIANI F., ZAGONI P. (Milan Collaborative Group for Studies on Epilepsy)
Long term intensive monitoring in the difficult patient. Preliminary results of 16 months of observations. Usefulness and limitations.
In : **Antiepileptic drug monitoring**, Gardner-Thorpe C., Janz D., Meinardi H., Pippenger C.E., Eds., Pitman Medical, pp. 197-213, 1977

14. BARUZZI A., BORDO B., **BOSSI L.**, CASTELLI D., GERNA M., TOGNONI G., ZAGNONI P.
Plasma levels of di-n-dipropylacetate and clonazepam in epileptic patients.
Int. J. Clin. Pharmacol., 15 : 403-408, 1977

15. **BOSSI L.**, MORSELLI P. L.

Hypnotics.
In : **Drug disposition during development. Morselli** P. L., Ed., Spectrum Publ., N.Y., pp. 361-392, 1977

16. MORSELLI P. L., BARUZZI A.,GERNA M., **BOSSI L.**, PORTA M.
Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain.
Br. J. Clin. Pharmacol., 4 : 535-540, 1977

17. VIANI F., AVANZINI G., BARUZZI A., BORDO B., **BOSSI L.**, CANGER R., PORRO M.G., RIBOLDI A., SOFFIENTINI M.E., ZAGNONI P., MORSELLI P. L. (Milan Collaborative Group for studies in Epilepsy)
Long term monitoring of antiepileptic drugs in patients with Lennox-Gastaut syndrome.
In : **Epilepsy, The Eight International Symposium**, Penry J.K., Ed., Raven Press, N.Y., pp. 131-138, 1977

1978

18. **BOSSI L.**
Anticonvulsivanti e psicofarmaci.
In : **Farmaci e gravidanza**, Mancini M., Tognoni G., Eds., Il Pensiero Scientifico, Roma, Anno XIV, N° 4, pp. 75-85, 1978

19. CANGER R., SPINA S., ALTAMURA C., **BOSSI L.**, PORRO M.G., SPAGNOLI A., COMO L., DE GIAMBATTISTA M., PARDI G., PIFAROTTI G., SPREAFICO R.
Livelli plasmatici dei farmaci antiepilettici in corso di gravidanza (risultati preliminari).
Lega Italiana contro l'Epilessia, Bollettino 22/23 : 267-272, 1978

1979

20. AVANZINI G., **BOSSI L.**, CARACENI T., CONSOLAZIONE A., FRANCESCHETTI S.
Possibli implicazioni del sistema serotoninergico nella patogenesi delle mioclonie.
Dati preliminari di uno studio clinico.
Riv. Ital. EEG Neurofisiol. Clin., 2 : 303-319, 1979

English abstract :
Possible role of the serotoninergic system in the pathogenesis of myoclonus.
Preliminary data of a clinical trial.
EEG Clin. Neurophysiol. 1981, p. 76

21. **BOSSI L.**
Effetti indesiderati dei farmaci antiepilettici : review della letteratura.
Lega Italiana contro l'Epilessia, Bollettino 25/26 : 5-29, 1979

22. **BOSSI L.**, AVANZINI G., BATTINO D., CANGER R., CROCI D., FRANCESCHETTI S., PORRO M.G., PRUNERI C., SPINA S., SPREAFICO R.
Monitorage des médicaments antiépileptiques pendant la grossesse. Signification clinique des modifications des niveaux plasmatiques des médicaments antiépileptiques. Expériences chez 30 malades.
Lyon Médical, 242 : 597-603, 1979

23. **BOSSI L.**, PORRO M.G., TOGNONI G.
Farmaci antiepilettici e psicofarmaci in gravidanza.
Rivista degli Ospedali. 11 : 271-281, 1979

24. FRANCESCHETTI S., **BOSSI L.**, CEFALA A., AVANZINI G.
Criteri elettrofisiologici di classificazione del mioclono : studio di 16 casi
Riv. Ital. EEG Neurofisiol. Clin., 3 : 17-20, 1979

English abstract :
Electrophysiological classification criteria for myoclonus. Study of 16 cases.
EEG Clin. Neurophysiol. 1980, 76

1980

25. AVANZINI G., **BOSSI L.**, CARACENI T., CONSOLAZIONE A., FRANCESCHETTI S., NEGRI S., PARATI E.
Effect of L-5HTP and drugs acting on serotonin metabolism in various myoclonic syndromes.
In : **Epilepsy - Clinical and experimental research, Monogr. Neurol. Sci.,** Vol. 5, pp. 142-152, Karger, Basel. 1980

26. AVANZINI G., FRANCESCHETTI S., CEFALA A., **BOSSI L.**, ROVEI V.
Effect of intravenous administration of clonazepam on myoclonus : comparative evaluation with serotonin precursors.
In : **Antiepileptic therapy - Advances in drug monitoring,** Johannessen S.I., Morselli P.L., Pippenger C.E., Richens A., Schmidt D., Meinardi H., Eds., Raven Press, N.Y., pp. 169-174, 1980

27. BATTINO D., **BOSSI L.**, CROCI D., FRANCESCHETTI S., GOMENI C., MOISE A., VITALI A.
Carbamazepine plasma levels in children and adults : influence of age and associated therapy.
Therapeutic Drug Monitoring, 2 : 315-322, 1980

28. BATTINO D., MOLTENI B. SPINA S., **BOSSI L.**, CANGER R., MARGSTAKLER E., ROSSI E.
Modificazioni del sistema emostatico in neonati da madri con epilessia in terapia cronica. Resultati preliminari.
In : **Progressi in epilettologia, 1980, Canger R., Avanzini G., Tassinari C.A., Eds., Lega Italiana contro l'Epilessia, Bolletino** 29/30, 223-225, 1980

29. **BOSSI L.**, ASSAEL B.M., AVANZINI G., BATTINO D., CACCAMO M. L., CANGER R., COMO M.L., PIFAROTTI G., DE GIAMBATTISTA M., FRANCESCHETTI S., MARINI A., PARDI G., PORRO M.G., ROVEI V., SANJUAN M., SOFFIENTINI M.E., SPINA S., SPREAFICO R.
Plasma levels and clinical effects of antiepileptic drugs in pregnant epileptic patients and their newborns.
In : **Antiepileptic therapy - Advances in drug monitoring**, Johannessen S.L., Morselli P.L., Pippenger C.E., Richens A., Schmidt D., Meinardi H., Eds., Raven Press, N.Y., pp. 9-14, 1980

30. **BOSSI L.,** ASSAEL B.M., AVANZINI G., BATTINO D., CACCAMO M.L., CANGER R., COMO M.L., PIFAROTTI G., DE GIAMBATTISTA M., FRANCESCHETTI S., MARINI A., PARDI G., PORRO M.G., ROVEI V., SANJUAN M., SOFFIENTINI M.E., SPINA S., SPREAFICO R.
Plasma level and clinical effects of antiepileptic drugs in pregnant epileptic patients and their newborns.
Obstetr. Gynecol. Surv., 35 : 561-562, 1980

31. **BOSSI L.**, AVANZINI G., BATTINO D., CANGER R., COMO M.L., CROCI D., DE GIAMBATTISTA M., FRANCESCHETTI S., PIFAROTTI G., PORRO M.G., PRUNERI C., SPINA S., SPREAFICO R.
Plasmaspiegelbestimmungen während der Schwangerschaft : Klinische Bedeutung von Änderungen des Plasmaspiegel.
In : **Epilepsie 1979**, Doose H., M., Gross-Selbeck G., Meinardi H., Eds., Georg Thieme Verlag, Stuttgart, pp. 16-22, 1980

32. **BOSSI L.**, BATTINO D., CACCAMO M.L., CANGER R., COMO M.L., DE GIAMBATTISTA M., MARINI A., PARDI G., PIFAROTTI G., PORRO M.G., ROVEI V., SANJUAN M., SERENI F.
Klinische und pharmakologische Beobachtungen bei 31 Neugeborenen von epileptischen Müttern.
In : **Epilepsie 1979**, Doose H., Dam M., Gross-Selbeck G., Meinardi H., Eds., Georg Thieme Verlag, Stuttgart, pp. 23-27, 1980.

33. CANGER R., AVANZINI G., BATTINO D., **BOSSI L.**, COMO M.L., CROCI D.,DE GIAMBATTISTA M., FRANCESCHETTI S., PARDI G., PIFAROTTI G., PRUNERI C., SPINA S., SPREAFICO R., STERZI R.
Drug monitoring and clinical evaluation of women with epilepsy : A prospective study.
In **: Advances in Epileptology, the XIth Epilepsy International Symposium**, Canger R., Angeleri F., Penry J.K., Eds., Raven Press, pp. 423-428, 1980.

34. MORSELLI P.L., BARUZZI A., **BOSSI L.**, AVANZINI G., FRANCESCHETTI S., CANGER R., VIANI F.
Intensive long-term monitoring in "resistant" epileptic patients. Results of a two-year study.
In **: Advances in Epileptology, the XIth Epilepsy International Symposium**, Wada J., Penry J.K., Eds. Raven Press, N.Y., pp. 99-107, 1980.

35. MORSELLI P.L., **BOSSI L.**

Biotransformation des médicaments chez le nouveau-né.
In : **Société Française d'Anesthésie et de Réanimation "Le foie en anesthésie et réanimation"**, Mars 1980, pp. 159-169.

36. MORSELLI P.L., **BOSSI L.**, HENRY J.F., ZARIFIAN E., BARTHOLINI G.
On the therapeutic action of SL 76002, a new GABA mimetic agent : preliminary observations in neuropsychiatric disorders.
Brain Res. Bull. 5 (suppl. 2) : 411-414, 1980.

37. MORSELLI P.L., FRANCO-MORSELLI R., **BOSSI L.**
Clinical pharmacokinetics in newborns and infants. Age related differences and therapeutic implications.
Clinical Pharmacokinetics 5 : 485-527, 1980.

1981

38. AVANZINI G., BATTINO D., BINELLI S., **BOSSI L.**, BRESCHI F., CACCAMO M.L., CANGER R., CEFALA A., COMO M.L., CROCI D., CUSI C., DE GIANBATTISTA M., FARRARIO G., FRANCESCHETTI S., LATIS G.O., MARINI A., MOISE A., NOLTENI B., PARDI G., PIFAROTTI G., SERENI F., SCHIRO G.P., SIMIONATO L. (Gruppo collaborativo milanese per lo studio dell'epilessia in gravidanza).
Gravidanza ed epilessia.
Notizie Sanità, 33, 52 : 126-132, 1981.

39. **BOSSI L.**, AVANZINI G., BATTINO D., CACCAMO M.L., CANGER R., COMO M.L., CROCI D., DE GIANBATTISTA M., FRANCESCHETTI S., PIFAROTTI G., PORRO M.G., PRUNERI C., SPINA S., SPREAFICO R.
Antiepileptic drug monitoring in pregnancy - clinical significance of changes of antiepileptic drug plasma levels.
In : **Epilepsy. Problems of marriage, pregnancy, genetic counselling**.
Gross-Selbeck G. and Doose H., Eds. Georg Thieme Publ., Stuttgart and New York, pp. 15-19, 1981.

40. **BOSSI L.**, BATTINO D., CACCAMO M.L., CANGER R., COMO M.L., DE GIANBATTISTA M., MARINI A., PARDI G., PIFAROTTI G., PORRO M.G., ROVEI V., SANJUAN M., SERENI F.
Plasma levels and clinical effects of antiepileptic drugs in newborns of chronically treated epileptic mothers.
In : **Epilepsy. Problems of marriage, pregnancy, genetic counselling**.
Gross-Selbeck G. and Doose H., Eds. Georg Thieme Publ., Stuttgart and New York, pp. 20-24, 1981.

41. **BOSSI L.**, ZIVKOVIC B., SCATTON B., DEDEK J., MUNARI C., STOFFELS C., BANCAUD J., TALAIRACH J., MORSELLI P.L.
Ventricular CSF concentrations of NA, DA, HVA and 5-HIAA in epileptic patients.
In : **Neurotransmitters and epilepsy**. Lloyd K.G., Löscher W., Meldrum B., Morselli P.L. and Reynolds T., Eds., Raven Press, pp. 307-322, 1981.

42. LLOYD K.G., MUNARI C., **BOSSI L.**, BANCAUD J., TALAIRACH J., MORSELLI P.L.
Function and dysfunction of the GABA system in the human brain.
In : **Transmitter biochemistry in human brain tissue**. Esdin E., and Riederer P., Eds., Mac Millan Publ., London, pp. 127-142, 1981.

43. LLOYD K.G., MUNARI C., **BOSSI L.**, STOFFELS C., TALAIRACH J., MORSELLI P.L.
Biochemical evidence for the alterations of GABA-mediated synaptic transmission in pathological brain tissue.
In : **Neurotransmitters and epilepsy**. Lloyd K.G., Löscher W., Meldrum B., Morselli P.L. and Reynolds T., Eds., Raven Press, pp. 325-334, 1981.

44. LLOYD K.G., MUNARI C., WORMS P., **BOSSI L.**, BANCAUD J., TALAIRACH J., MORSELLI P.L.
The role of GABA mediated neurotransmission in convulsive states.
In : **GABA and Benzodiazepines Receptors**, Costa E., Di Chiara G. and Gessa G.L., Eds., Raven Press, New York, pp. 199-206, 1981.

45. LLOYD K.G., WORMS P., **BOSSI L.**, MORSELLI P.L.
Prediction of the clinical anticonvulsant effects of a GABA agonist by its neuropharmacological spectrum.
In : **Advances in Epileptology, the XIIth Epilepsy International Symposium**, Dam M., Gram L. and Penry J.K. Eds., Raven Press, N.Y., pp. 19-24, 1981.

46. LOISEAU P., CENRAUD B., **BOSSI L.**, MORSELLI P.L.
Double-blind, cross-over trial with progabide versus placebo in severe epilepsy.
In : **Advances in Epileptology, the XIIth Epilepsy International Symposium**
Dam M., Gram L. and Penry J.K. Eds., Raven Press, N.Y., pp. 135-140, 1981.

47. MUNARI C., STOFFELS C., BANCAUD J., TALAIRACH J., **BOSSI L.**, MORSELLI P.L.
Concentrazioni cerebrali dei farmaci antiepilettici in pazienti con epilessia ad eziologia tumorale
Legale Italiana contro l'Epilessia, Bollettino 32/33, 37-39, 1981.

48. MUNARI C., STOFFELS C., **BOSSI L.**, BONIS A., TALAIRACH J., BANCAUD J.
Automatic activities during frontal and temporal lobe seizures : are they the same ?
In : **Advances in Epileptology, the XIIth Epilepsy International Symposium**, Dam M., Gram L. and Penry J.K. Eds., Raven Press, N.Y., pp. 287-292, 1981.

49. SEMERDJIAN-ROUQUIER L., **BOSSI L.**, SCATTON B.
Determination of 5-hydroxytryptophan, serotonin and 5-hydroxyindolacetic acid in rat and human brain and biological fluids by reversed-phase high-performance liquid chromatography with electrochemical detection.
J. Chromatography, 218 : 663-670, 1981.

50. VAN DER LINDEN G.J., MEINARDI H., MEIJER J.W.A., **BOSSI L.**, GOMENI C.

A double-blind, cross-over trial with progabide (SL 76002) against placebo in patients with secondary generalized epilepsy.
In : **Advances in Epileptology, the XIIth Epilepsy International Symposium**, Dam M., Gram L. and Penry J.K. Eds., Raven Press, N.Y., pp. 141-144, 1981.

1982

51. BATTINO D., AVANZINI G., **BOSSI L.**, CANGER R., COMO M.L., CROCI D., SPINA S.
Monitoring of antiepileptic drug plasma levels during pregnancy and puerperium.
In : **Epilepsy, Pregnancy and the Child**. Janz D., **Bossi L.**, Dam H., Helge H., Richens A. and Schmidt D. Eds., Raven Press., N.Y., pp. 147-154, 1982

52. BATTINO D., **BOSSI L.**, CANGER R., COMO M.L., DE GIAMBATTISTA M., OLDRINI A., PARDI G., PIFAROTTI G.
Obstetrical monitoring of pregnancy in 59 patients with epilepsy.
In : **Epilepsy, Pregnancy and the Child**. Janz D., **Bossi L.**, Dam H., Helge H., Richens A., and Schmidt D. Eds., Raven Press., N.Y., pp. 99-102, 1982.

53. BATTINO D., **BOSSI L.**, CANGER R., MARGSTAKLER E., MOLTENI B., ROSSI E., SPINA S.
Coagulation function in newborns treated in utero with antiepileptic drugs.
In : **Epilepsy, Pregnancy and the Child**. Janz D., **Bossi L.**, Dam H., Helge H., Richens A. and Schmidt D. Eds., Raven Press, N.Y., pp. 383-386, 1982

54. **BOSSI L.**
Fetal effects of anticonvulsants.
In : **Antiepileptic Therapy in Children**. Morselli P.L., Pippenger J. and Penry J.K. Eds., Raven Press, pp. 37-64, 1982

55. **BOSSI L.**
Neonatal period including drug disposition in newborns : a review of the literature.
In : **Epilepsy, Pregnancy and the Child**. Janz D., **Bossi L.**, Dam H., Helge H., Richens A. and Schmidt D. Eds., Raven Press, N.Y., pp. 327-342, 1982

56. **BOSSI L.**, BATTINO D., BOLDI B., CACCAMO M.L., FERRARIS G., LATIS G.O., SIMIONATO L.
Anthropometric data and minor malformations in newborns of epileptic mothers.
In : **Epilepsy, Pregnancy and the Child**. Janz D., **Bossi L.**, Dam H., Helge H., Richens A. and Schmidt D. Eds., Raven Press, N.Y., pp. 299-302, 1982

57. **BOSSI L.**, BATTINO D., CACCAMO M.L., DE GIAMBATTISTA M., LATIS G.O., OLDRINI A., SPINA S.
Pharmacokinetics and clinical effects of antiepileptic drugs in newborns of chronically treated epileptic mothers.
In : **Epilepsy, Pregnancy and the Child**. Janz D., **Bossi L.**, Dam H., Helge H., Richens A. and Schmidt D. Eds., Raven Press, N.Y., pp. 373-382, 1982

58. **BOSSI L.**, MUNARI C., STOFFELS C., BONIS A., BACIA T., TALAIRACH J., BANCAUD J.
Manifestations motrices et posturales dans les crises d'épilepsie d'origine temporale.
Rev. E.E.G. Neurophysiol., 12 : 101-106, 1982

59. **BOSSI L.**, MUNARI C., BONIS A., TALAIRACH J., BACIA T., BANCAUD J.
Somatomotor manifestations in temporal lobe seizures.
In : **Advances in Epileptology, the XIIIth Epilepsy International Symposium**, Akimoto H., Kazamatsuri H., Seino M. and Ward A.A., Eds. Raven Press, pp. 29-32, 1982

60. CANGER R., AVANZINI G., BATTINO D., **BOSSI L.**, FRANCESCHETTI S., SPINA S.
Modifications of seizure frequency in pregnant patients with epilepsy. A prospective study.
In : **Epilepsy, Pregnancy and the Child**. Janz D., **Bossi L.**, Dam H., Helge H., Richens A., and Schmidt D. Eds., Raven Press, N.Y., pp. 33-38, 1982

61. MORSELLI P.L., **BOSSI L.**
Carbamazepine : absorption, distribution and excretion.
In : **Antiepileptic drugs (2nd edition),** Woodbury D.M., Penry J.K., Pippenger C.E., Eds., Raven Press, Chapter 39, pp. 465-482, 1982

62. MORSELLI P.L., **BOSSI L.**, MUNARI C.
Should EEG recordings be included in clinical trials on new AEDs ?
In : **Henry Gastaut and the Marseille School's contribution to the Neurosciences**, EEG suppl. 35. Cobb W.A. and Van Duyn H., Eds., Elsevier Publ., Amsterdam, pp. 46-50, 1982

63. MUNARI C., **BOSSI L.**, STOFFELS C., BRUNET P., BANCAUD J., TALAIRACH J., MORSELLI P.L.
Concentrations cérébrales des médicaments anti-comitiaux chez les malades ayant une épilepsie tumorale.
Rev. E.E.G. Neurophysiol., 12 : 38-43, 1982

64. MUNARI C., STOFFELS C., **BOSSI** L., BRUNET P., BONIS A., BANCAUD J., TALAIRACH J.
Partial seizures with elementary or complex symptomatology : a valid classification for temporal lobe seizures ?
In : **Advances in Epileptology**, the XIIIth Epilepsy International Symposium, Akimoto H., Kazamatsuri H., Seino M. and Ward A.A., Eds. Raven Press, pp. 25-27, 1982

1983

65. BATTINO D., AVANZINI G., **BOSSI L.**, CROCI D., CUSI C., GOMENI C., MOISE A.
Plasma levels of primidone and its metabolite phenobarbital : effect of age and associated therapy.
Therapeutic drug monitoring, 5 : 73-79, 1983

66. LLOYD K.G., MUNARI C., WORMS P., **BOSSI L.**, MORSELLI P.L.
Indications for the use of Gamma-aminobutyric acid (GABA) agonists in convulsive disorders.
In : **Epilepsy, an Update on Research and Therapy**, Alan R. Liss, Inc., New York, pp. 285-297, 1983

67. LOISEAU P., **BOSSI L.**, GUYOT M., OROFIAMMA B., MORSELLI P.L.
Double blind crossover trial of progabide versus placebo in severe epilepsies.
Epilepsia, 24 : 703-715, 1983

1984

68. BATTINO D., BINELLI S., **BOSSI L.**, CANGER R., COMO M.L., CROCI D., CUSI C., DE GIANBATTISTA M., PARDI G., AVANZINI G.
Monitoring of antiepileptic drugs and hormones in pregnant epileptic women.
In : **Advances in Epileptology, the XVth Epilepsy International Symposium**, Porter R.J. et al. Eds., Raven Press, New York, pp. 227-232, 1984

69. BATTINO D., BINELLI S., **BOSSI L.**, COMO M.L., CROCI D., CUSI C., AVANZINI G.
Changes in primidone/phenobarbital ratio during pregnancy and puerperium.
Clin. Pharmacokin., 9 : 252-260, 1984

70. **BOSSI L.**, MUNARI C., STOFFELS C., BONIS A., BACIA T., TALAIRACH J., BANCAUD J.
Somatomotor manifestations in temporal lobe seizures.
Epilepsia, 25 (1) : 70-76, 1984

71. LLOYD K.G., MUNARI C., **BOSSI L.**, MORSELLI P.
Neurochemical evidence for the GABA hypothesis of human epilepsy.
In : **Advances in Epileptology, the XVth Epilepsy International Symposium**, Porter R.J. et al. Eds. Raven Press, New York, pp. 3-8, 1984

72. LOISEAU P., **BOSSI L.**, COURJON J., GAREL S., KURTZ D., MEAULLE F., MICHELETTI G., MUSCH B., OROFIAMMA B., VERCELLETTO P., MORSELLI P.L.
Multicenter comparative trial of progabide versus sodium valproate in therapy resistant epilepsies : preliminary results.
In : **Advances in Epileptology, the XVth Epilepsy International Symposium**, Porter R.J. et al, Eds. Raven Press, New York, pp. 347-353, 1984

73. MARTINEZ-LAGE M.J., **BOSSI L.**, MORALES G., MARTINEZ VILA E., OROFIAMMA B., VITERI C.
Progabide treatment in severe epilepsy : A double blind cross-over trial versus placebo.
Epilepsia, 25 (5) : 586-593, 1984

74. MORSELLI P.L., **BOSSI L.**
Farmaci GABA-agonisti come nuovi agenti antiepilettici.

In : **Attualità e prospettive in tema di terapia dell'epilessia e monitoraggio dei farmaci**. Monaco F., Ed., Edizioni Libreria Cortina, Torino, pp. 93-104, 1984

75. MORSELLI P.L., LOISEAU P., MARTINEZ-LAGE J.M., **BOSSI L.**
Long term follow-up with progabide in resistant epilepsies.
In : **Advances in Epileptology, the XVth Epilepsy International Symposium**, Porter R.J. et al, Eds. Raven Press, New York, pp. 177-180, 1984

76. WALLACE S., **BOSSI L.**
Response conditional two-period crossover trial of progabide versus ethosuximide in absence seizures.
In : **Advances in Epileptology, the XVth Epilepsy International Symposium**, Porter R.J. et al, Eds. Raven Press, New York, pp. 343-346, 1984

1985

77. **BOSSI L.**, BEAUSSART M., COURJON J., FOURNIER V., GAREL S., KURTZ D., MARESCAUX C., MEAULLE F., MICHELETTI G., OLSEN J., OROFIAMMA B., VERCELLETTO P., WEISS E., LOISEAU P.
Multicenter comparative trial of progabide versus sodium valproate in therapy resistant epilepsies.
In : **Epilepsy and GABA receptor agonists, basic and therapeutic research**, Bartholini G., **Bossi L.**, Lloyd K.G. and Morselli P.L., Eds. Raven Press, New York, pp. 415-420, 1985

78. COQUELIN J.P.H., KRALL R., **BOSSI L.**, MUSCH B., MORSELLI P.L.
Drug safety profile of progabide.
In : **Epilepsy and GABA receptor agonists, basic and therapeutic research**, Bartholini G., **Bossi L.**, Lloyd K.G. and Morselli P.L., Eds. Raven Press, New York, pp. 431-440, 1985

79. DANDELOT J.B., MIGNARD C., MIGNARD D., BOUSQUET C., CHOUCAIR Y., NAKACHE P., POULAIN D., **BOSSI L.**
Progabide monotherapy in naive epileptic patients in the Réunion Island.
In : **Epilepsy and GABA receptor agonists, basic and therapeutic research**, Bartholini G., **Bossi L.**, Lloyd K.G. and Morselli P.L., Eds. Raven Press, New York, pp. 409-414, 1985

80. DULAC O., **BOSSI L.**, REGNIER F., POULAIN D., BATTIN J., DROSSART F., DANDELOT J.B., BERTSCH M., ARTHUIS M.
Long term open trial of progabide in epileptic children.
In **: Epilepsy and GABA receptor agonists, basic and therapeutic research**, Bartholini G., **Bossi L.**, Lloyd K.G. and Morselli P.L., Eds. Raven Press, New York, pp. 389-398, 1985

81. LLOYD K.G., **BOSSI L.**, MORSELLI P.L., ROUGIER M., LOISEAU P., MUNARI C.
Biochemical evidence for dysfunction of GABA neurons in human epilepsy.

In : **Epilepsy and GABA receptor agonists, basic and therapeutic research**, Bartholini G., **Bossi L.**, Lloyd K.G. and Morselli P.L., Eds. Raven Press, New York, pp. 43-52, 1985

82. MORSELLI P.L., **BOSSI L.**
Antiepileptic efficacy of GABA agonists in humans.
In : **Neurotransmitters, seizures and epilepsy II**, edited by Fariello R.G., Morselli P.L., Lloyd K.G., Quesnay L.F. and Engel J., Eds. Raven Press, New York, pp. 253-261, 1985

83. MORSELLI P.L, FOURNIER V., **BOSSI L.**, MUSCH B.
Clinical activity of GABA agonists in neuroleptic and L-dopa induced dyskinesia.
In : **Dyskinesia - Research and Treatment** : Proceedings of the International Symposium on Dyskinesia in Kolle-Kolle, Copenhague, Danemark, 17-18 May 1984, edited by Casey, Chase, Christensen, Gerlach, Springer Verlag, Berlin- Heidelberg, pp. 128-136, 1985

84. WEBER M., VESPIGNANI H., REMY M.C., REGNIER F., **BOSSI L.**
Controlled trial of progabide versus placebo in severe therapy resistant epilepsies.
In : **Epilepsy and GABA receptor agonists, basic and therapeutic research**, Bartholini G., Bossi L., Lloyd K.G. and Morselli P.L. Eds. Raven Press, New York, pp. 353-361, 1985

1986

85. LLOYD K.G., **BOSSI L.**, MORSELLI P.L.
Studies on GABA synaptic Function in the epileptic focus.
In : **Workshop on intractable epilepsy**, edited by Schmidt G. and Morselli P.L. Eds. Raven Press. New York, 1986

86. LLOYD K.G., **BOSSI L.**, MORSELLI P.L., MUNARI C., ROUGIER M., LOISEAU P.
Alterations of GABA-mediated synaptic transmission is human epilepsy.
In : **Basic mechanisms of the Epilepsies**. 2nd Edition, Delgado Escueta and al. Eds Raven Press. New York, 1986

87. LLOYD K.G., MUNARI C., **BOSSI L.**, MORSELLI P.L.
The GABA hypothesis of human epilepsy : neurochemical evidence from surgically resected identified foci.
WONIEP II, Eds. Raven Press. New York, 1986

88. MORSELLI P.L., **BOSSI L.**
Antiepileptic efficacy of GABA agonists in man.
In : **Workshop on intractable epilepsy**, edited by Schmidt G. and Morselli P.L. Eds Raven Press. New York, 1986

89. MUSCETTOLA G., CASTELLO M. GIANNINI G., **BOSSI L.**
Open pilot study of progabide in depression.

In : **GABA and mood disorders : animal and clinical studies**, Bartholini G., Lloyd K.G., Morselli P.L., Musch B., Eds. Raven Press, New York, pp. 113-118, 1986

90. PERRIS C., TJALLDEN G., **BOSSI L.**, PERRIS H.
Progabide versus nortriptyline in depression : a controlled trial.
In : **GABA and mood disorders : animal and clinical studies**, Bartholini G., Lloyd K.G., Morselli P.L., Musch B., Eds. Raven Press. New York, pp. 135-138, 1986

1989

91. **BOSSI L.**, GAILLOT J.
Taux sanguins - Effets secondaires.
In : **Dictionnaire des neuroleptiques**. Colonna L., Petit M., Lépine J.P. Eds. Médicales Spécia. pp. 373-381, 1989

1990

92. **BOSSI L.**
Ramon y Cajal - L'innamorato del cervello
Fidia Biomedical Information, 1990

1993

93. **BOSSI L.**
L'âme électrique.
L'âme au corps, Catalogue de l'esposition, Commissaire : Jean Clair, Ed. Gallimard & Editions des Musées de France, Paris 1993

1994

94. COCITO L., BIANCHETTI A., **BOSSI L.**, GIBERTI L., LOEB C.
GABA and phosphatidylserine in human photosensitivity : a pilot study.
Epilepsy Research 17 (1994), pp. 49-53.

1998

95. BOSSI L.
Disease-modifying treatment for Alzheimer's disease : the neurotrophic approach.
Alzheimer's reports, Vol.1, Suppl.1, November 1998, S29

1999

96. **BOSSI L.**
Agalmophilie. In : **L'amour de l'art**, Hommage à Paolo Cadorin, Milan, Charta, 1999

2001

97. **BOSSI L.**
On "The hidden structure. A scientific biography of Camillo Golgi " , by Paolo

Mazzarello.
J Hist Neurosciences, 10 :326-328, 2001

98. **BOSSI L.**
The future of death.
Nexus conference, Nexus, Tilburg 2001

2002

99. GAMELIN E., GAMELIN L., **BOSSI L.,** QUASTHOFF S.
Clinical aspects and molecular basis of oxaliplatin neurotoxicity : Current management and development of preventive measures
Seminars in Oncology, 29 (Suppl.15): 21-33, 2002

2003

100. BOSSI L.
Les chimères existent-elles ?
In : **Chimères**, D. Ottinger (ed.), Actes Sud, Arles, 2003

ABSTRACTS

1975

SANKT-MORITZ - 6-7 January 1975
Epileptic seizures, behavior and pain - An International Symposium
MORSELLI P.L., **BOSSI L**., GERNA M.
Pharmacokinetic studies with carbamazepine in epileptic patients.

GENOVA - April 19 1975
Convulsività infantile. Riunione di aggiornamento della sezione per la neurologia pediatrica della S.I.N.P.I.
BARUZZI A., **BOSSI L**., CASTELLI D., GERNA M., RIGHETTI A., MORSELLI P.L.
Alcune considerazioni della farmacodinamica dei farmaci anticonvulsivanti nell'eta evolutiva.

MILANO - November 1975
Convegno Regionale su "Farmaci e gravidanza", organizzato dal Centro Regionale Informazione Farmaci sotto il patrocinio della Regione Lombardia.
BOSSI L.
Psicofarmaci e gravidanza.

ANZIO (ROME) - December 1975
Convegno Interregionale "Farmaci e Gravidanza" Serono Simposi.
BOSSI L.
Psicofarmaci e gravidanza.

1976

ANCONA - January 1976
Giornata di aggiornamento sulle epilessie.
BOSSI L.
Il monitoraggio dei livelli plasmatici dei farmaci antiepilettici.

BOLOGNA - April 29 1976
Riunione della Sezione Emilia-Romagna della Societa Italiana di Neuropsichiatra Infantile, "Le epilessie miocloniche in età evolutiva".
BARUZZI A., **BOSSI L.**, MORSELLI P.L.
Concentrazione plasmatiche di di-n-propilacetato di sodio e clonazepam nei pazienti epilettici.

ROME - May 1976
Riunione di aggiornamento sulla terapia delle epilessie. Clinica delle Malattie Nervose e Mentali e Clinica Neurologica dell'Università Cattolica di Roma, Policlinico Gemelli, Rome.
BOSSI L.
Farmacoresistenza e monitoraggio di farmaci anti-epilettici.

ANACAPRI - June 1976
Convegno della Società Italiana di Neuropsicofarmacologia.
TOGNONI G., BARUZZI A., **BOSSI L.**, ZAGNONI P.
Sperimentazione clinica o critica della pratica medica ?

DUBLIN - September 1976
VIIIth Epilepsy International Symposium.
VIANI F., AVANZINI G., BARUZZI A., BORDO B., **BOSSI L.**, CANGER R., PORRO M.G., SOFFIENTINI M.E., ZAGNONI P., MORSELLI P.L.
Long term monitoring of antepileptic drugs in patients with the Lennox-Gastaut syndrome.

EXETER - September 1976
WODADIBOF III (Workshop on the determination of antiepileptic drugs in body fluids. III)
AVANZINI G., BARUZZI A., BORDO B., **BOSSI L.**, BRESCHI F., CANGER R., DE CASTRO R., FRANCESCHETTI S., GERNA M., MORSELLI P.L., PIGNATELLI G., PRUNERI C., SMIRNE S., VIANI F., ZAGNONI P. (Milan collaborative Group for Studies on Epilepsy).
Long term monitoring in the difficult patient. Preliminary results of 16 months of observations - Usefulness and limitations.

PAVIA - 30 September - 3 October 1976
VIIth International Symposium on Clinical Pharmacology.
BARUZZI A., BORDO B., **BOSSI L.**, CASTELLI D., GERNA M., ZAGNONI P., TOGNONI G.
Plasma levels of di-n-dipropylacetate and clonazepam in epileptic patients.
Abstract.

TAORMINA - 25-26 February 1976 (member of Scientific Committee)

IV Riunione annuale della Lega Italiana contro l'Epilessia
BOSSI L., PORPO M.G., BARUZZI A.
Farmaci antiepilettici e gravidanza : valutazione rischi-benefici.

BARUZZI A., BORDO B., **BOSSI L.**, CASTELLI D., GERNA M., PORRO M.G., RIGHETTI A; SOFFIENTINI M.E., ZAGNONI P., MORSELLI P.L., AVANZINI G., BRESCHI F., FRANCESCHETTI S., CANGER R., DE CASTRO R., PRUNERI C., PIGNATELLI G., SMIRNE R., VIANI F.
Monitoraggio intensivo dei farmaci antiepilettici : risultati generali di un'osservazione durata due anni.

AVANZINI G., FRANCESCHETTI S., BARUZZI A., BORDO B., **BOSSI L.**, MORSELLI P.L., PORRO M.G., ZAGNONI P., CANGER R., PRUNERI C., VIANI F. (Gruppo Milanese per lo studio delle Epilessie)
Problemi terapeutici nell'epilessia con crisi parziali : considerazioni su un'esperienza di monitoraggio a lungo termine clinico-farmacologico.

VIANI F., RIBOLDI A., ROSSOTTI V., BARUZZI A., **BOSSI L.**, MORSELLI P.L., SOFFIENTINI M.E., ZAGNONI P., AVANZINI G., FRANCESCHETTI S., CANGER R.
Monitoraggio a lungo termine dei farmaci antiepilettici : risultati in pazienti con sindrome di Lennox-Gastaut

PAZZAGLIA P., AMBROSETTO G., FORTI A., SACQUEGNA T., LUGARESI E., BARUZZI A., **BOSSI L.**, PORRO M.G., ZAGNONI P.
Il trattamento delle crisi epilettiche parziali con il phenobarbital, la difenilidantoina e la carbamazepina : studio longitudinale (4-22 mesi) guidato dalla determinazione dei livelli plasmatici dei farmaci.

1977

MILANO - March 1977
Seminario : "La terapia farmacologica delle epilessie", organizzato dal Centro Regionale di Informazione sui Farmaci e dalla Sezione Lombarda della Lega Italiana contro l'Epilessia.
BOSSI L.
Risultati e prospettive del piano di monitoraggio delle concentrazioni plasmatiche dei farmaci antiepilettici dell'Università
BOSSI L.
Psicofarmaci e antiepilettici.

1978

VERONA - April 1978
Epilessie e mondo del lavoro
BOSSI L.
Effetti collaterali e teratogeni dei farmaci antiepilettici

LLORET DE MAR (BARCELONA) - May 1978
1a riunione congiunta franco-italo-spagnola delle Leghe contro l'Epilessia

CANGER R., SPINA S., ALATAMURA C., **BOSSI L.**, PORRO M.G., SPAGNOLI A., COMO L., DE GIAMBATTISTA M., PARDI G., PIFAROTTI G., SPREAFICO R.
Livelli plasmatici dei farmaci antiepilettici in corso di gravidanza (risultati preliminari).

FLORENCE - June 1978
Riunione di Primavera della Società Italiana di Elettroencefalografia e Neurofisiologia
AVANZINI G., **BOSSI L.,** CARACENI T., CONSOLAZIONE A., FRANCESCHETTI S.
Possibli implicazioni del sistema serotoninergico nella patogenesi delle mioclonie.

VANCOUVER (CANADA) - September 1978
Xth Epilepsy International Symposium :

MORSELLI P.L., BARUZZI A., **BOSSI L.**, AVANZINI G., FRANCESCHETTI S., CANGER R., VIANI F.
Intensive long-term monitoring in "resistant" epileptic patients. Results of a two-year follow-up.
Abstracts, pp. 16-17

BOSSI L., AVANZINI G., CACCAMO M.L., CANGER R., COMO M.L., DE GIAMBATTISTA M., PARDI G., PIFAROTTI G., PORRO M.G., SPINA S., SPREAFICO R., TOGNONI G. (Milano Collaborative Group)
Drug monitoring and clinical evaluation of pregnant epileptic women and their newborns. Preliminary results of a prospective study.
Abstracts, p. 183

MILANO - October 1978
Corso aggiornamento in medicina perinatale. Clinica Ostetrica e Clinica Pediatrica dell'Università di Milano.
BOSSI L.
Farmaci antiepilettici in gravidanza : review della letteratura e dati preliminari di uno studio prospettico

FLORENCE - 21 October 1978
Conferenza di aggiornamento su "Reazioni avverse dei farmaci antiepilettici"
BOSSI L.
Effetti indesirati dei farmaci antiepilettici

PONT-A-MOUSSON - October 1978
4ème colloque International de Biologie Prospective
BOSSI L., MORSELLI P.L.
Métabolisme et pharmacocinétique des médicaments pendant la période néonatale

WARSAW (POLAND) - October 1978
Second European Regional Conference on Epilepsy
AVANZINI G., **BOSSI L.**, CARACENI T., CONSOLAZIONE A., FRANCESCHETTI S., NEGRI S., PARATI E.
Effect of L-5HTP and drugs acting on serotonin metabolism in various myoclonic syndromes.

1979

PARIS - March 1979
XIème Réunion Internationale d'Anesthésie-Réanimation, CHU Pitié-Salpêtrière
MORSELLI P.L., **BOSSI L.**
Biotransformation des médicaments chez le nouveau-né

LYON - 29 April 1979
Colloque de Chimiothérapie Antiépileptique
BOSSI L., AVANZINI G., BATTINO D., CANGER R., CROCI D., FRANCESCHETTI S., PORRO M.G., PRUNERI C., SPINA S ., SPREAFICO R.
Monitorage des médicaments antiépileptiques pendant la grossesse. Signification clinique des modifications des niveaux plasmatiques des médicaments antiépileptiques. Expériences cliniques chez 30 malades.

KIEL - May 1979
Tagung der Deutschen, Holländischen und Schweizerischen Sektionen der Internationalen Liga gegen Epilepsie
BOSSI L., AVANZINI G., BATTINO D., CANGER R., COMO M.L., CROCI D., DE GIAMBATTISTA M., FRANCESCHETTI S., PIRAFOTTI G., PORRO M.G., PRUNERI C., SPINA S., SPREAFICO R.
Plasmaspiegelbestimmungen während der Schwangerschaft : Klinische Bedeutung von Änderungen des Plasmaspiegel.

BOSSI L., BATTINO D., CACCAMO M.L., CANGER R., COMO M.L., DE GIAMBATTISTA M., MARINI A., PARDI G., PIFAROTTI G., PORRO M.G., ROVEI V., SANJUAN M., SERENI F.
Klinische und pharmakilogische Beobachtungen bei 31 Neugeborenen von epileptischen Müttern.

ALGHERO - June 1979
Riunione di Primavera della Società Italiana di Elettroencefalografia e Neurofisiologia
FRANCESCHETTI S., **BOSSI L.**, CEFALA A., AVANZINI G.
Criteri elletrofisiologici di classificazione del mioclono : studio di 16 casi.

OSLO - June 1979
WODADIBOF IV (Workshop on the determination of Antiepileptic drugs in Body fluids)
BOSSI L., ASSAEL B.M., AVANZINI G.,BATTINO D., CACCAMO M.L., CANGER R., COMO M.L., PIFAROTTI G., DE GIAMBATTISTA M, FRANCESCHETTI S., MARINI A., PARDI G., PORRO M.G., ROVEI V., SANJUAN M., SOFFIENTINI M.E., SPINA S., SPREAFICO R.
Plasma levels and clinical effects of antiepileptic drugs in pregnant epileptic patients and their newborns.

AVANZINI G., **BOSSI L.**, FRANCESCHETTI S., ROVEI V., SANJUAN M.
Quantitative evaluation of the effects of clonazepam and serotoninergic drugs in myoclonus

FLORENCE - 31 September - 3 October 1979
Xith Epilepsy International Symposium :

BOSSI L., BATTINO D., CACCAMO M.L., CANGER R., COMO M.L., DE GIAMBATTISTA M., MARINI A., PARDI G., PIFAROTTI G., PORRO M.G., ROVEI V., SANJUAN M., SERENI F.
Plasma levels and clinical effects of antiepileptic drugs in newborns of chronically treated epileptic mothers.
Abstracts, pp. 143-144

CANGER R., AVANZINI G., BATTINO D., **BOSSI L.**, COMO M.L., CROCI D., DE GIAMBATTISTA M., FRANCESCHETTI S., PARDI G., PIFAROTTI G., PRUNERI C., SPINA S., SPEAFICO R., STERZI R.
Drug monitoring and clinical evaluation of women with epilepsy : A prospective study.
Abstracts, pp. 130-131

COMO M.L., PIFAROTTI G., DE GIAMBATTISTA M., BATTINO D., **BOSSI L.**, CANGER R., SPINA S., PARDI G.
Epilepsy during pregnancy - a prospective follow-up.
Abstracts, p. 196

BATTINO D., BRESCHI F., **BOSSI L.**, CROCI D., FRANCESCHETTI S., MOISE A.
Carbamazepine plasma levels in children (poster)
Abstracts, p. 179

BEGHI E., **BOSSI L.**, PORRO M.G., SASANELLI F., SPAGNOLIA A., TOGNONI G.
Diagnosis and treatment of epileptic patients in hospital practice in Lombardy
Abstracts, p. 183

FRANCESCHETTI S., **BOSSI L.**, CEFALA A., AVANZINI G.
Clinical and neurophysiological evaluation of the effects of L-5HTP on myoclonus
Abstracts, p. 139

BATTINO D., **BOSSI L.**, CROCI D., CUSI C., GOMENI C., MOISE A., SPINA S.
Plasma levels of primidone and phenobarbital in children and adults : influence of age and associated therapy

MYRTLE BEACH (U.S.A.) - 6-10 November 1979
International Symposium on GABA and other inhibitory neurotransmitters
MORSELLI P.L., **BOSSI L.**, HENRY J.F., ZARIFIAN E., BARTHOLINI G.
Preliminary observations on the action of SL 76002, a new GABA-mimetic compound, in neuropsychiatric disorders
Abstract : Brain Res. Bull. 4 : 692, 1979

1980

AIX EN PROVENCE - 11-15 May 1980
IIème Réunion commune des Ligues espagnoles, italienne et française contre l'épilepsie
BATTINO D., **BOSSI L.**, MARGSTALKER E., MOLTENI B., ROSSI E., SPINA S.
Modificazioni del sistema emostatico in neonati da madre epilettiche in terapia cronica. Risultati preliminari.

PORTO CERVO (CAGLIARI) - May 1980
International Symposium on GABA and glutamate as neurotransmitters
LLOYD K.G., MUNARI C., WORMS P., **BOSSI L.**, BANCAUD J., TALAIRACH J., MORSELLI P.L.
The role of GABA mediated neurotransmission in convulsive states.

GOTEBORG (SUEDE) - 21-22 June 1980
Neuropsychopharmacologia, International Meeting
LLOYD K.G., MUNARI C., **BOSSI L.**, BANCAUD J., TALAIRACH J., MORSELLI P.L.
Function and dysfunction of the GABA system in the human brain.

COLMAR (STRASBOURG) - 10-11 July 1980
XXVIIIth International Congress of Physiological Sciences, « Amino Acid Transmitters »
LLOYD K.G., WORMS P., **BOSSI L.**, HENRY J.F., MORSELLI P.L.
Neuropharmacological actions of GABA agonists : predictability of their clinical usefulness
Abstract

COPENHAGEN - 6-10 September 1980
XIIth Epilepsy International Symposium :

LLOYD K.G., WORMS P., **BOSSI L.**, MORSELLI P.L.
GABA agonists : predictability for clinical usefulness by their neuropharmacological spectrum.
Abstract, Acta Neurol. Scand. Suppl. 79, 62 : 6, 1980

LOISEAU P., **BOSSI L.**, CENRAUD B., MORSELLI P.L.
A double-blind controlled study versus placebo with Progabide (SL 76002) in severe epilepsy
Abstracts, Acta Neurol. Scand. Suppl. 79, 62 : 20-21, 1980

VAN DER LINDEN G.J., MEINARDI H., MEIJER J.W.A., **BOSSI L.**, GOMENI C.
A double-blind cross-over trial with SL 76002 against placebo in patients with secondary generalized epilepsy.
Abstracts, Acta Neurol. Scand. Suppl. 79, 62 : 21, 1980

STOFFELS C., MUNARI C., **BOSSI L.**, BONIS A., BANCAUD J., TALAIRACH J.
A stereo-EEG study of epileptic seizures with genital and sexual symptomatology
Abstracts, Acta Neurol. Scand. Suppl. 79, 62 : 95, 1980

MUNARI C., BONIS A., STOFFELS C., **BOSSI L.**, TALAIRACH J., BANCAUD J.
Automatic activities during frontal and temporal lobe seizures : are they the same ?
Abstracts, Acta Neurol. Scand. Suppl. 79, 62 : 101, 1980

BATTINO D, AVANZINI G., **BOSSI L.**, CROCI D., CUSI C., GOMENI C., MOISE A., SPINA S.
Primidone and derived phenobarbital plasma concentrations in children (poster).
Abstracts, Acta Neurol. Scand. Suppl. 79, 62 : 101, 1980

BERLIN - 14-16 September 1980 (member of Scientific Committee, chairperson)
1st Workshop on Epilepsy, pregnancy and the child (sponsored by Epilepsy International):

CANGER R., AVANZINI G., BATTINO D., **BOSSI L.**, FRANCESCHETTI S., SPINA F.
Modification of seizure frequency in pregnant patients with epilepsy : a prospective study.
Abstract : Epilepsia, 22 : 365, 1981

BATTINO D., **BOSSI L.**, CANGER R., COMO M.L., CROCI D., SPINA S.
Monitoring of pregnancy in 59 patients with epilepsy.
Abstract : Epilepsia, 22 : 366, 1981

BATTINO D., AVANZINI G., **BOSSI L.**, CANGER R., COMO M.L., CROCI D., SPINA S.
Monitoring of antiepileptic drug plasma levels during pregnancy and puerperium.
Abstract : Epilepsia, 22 : 372, 1981

BOSSI L., BATTINO D., BOLDI B., CACCAMO M.L., FERRARIS G., LATIS G.O., SIMIONATO L.
Anthropometric data and minor malformations in newborns of epileptic mothers.
Abstract : Epilepsia, 22 : 374, 1981

BOSSI L., BATTINO D., CACCAMO M.L., DE GIAMBATTISTA ., LATIS G.O., OLDRINI A., ROSSI F., SPINA S.
Pharmacokinetics and clinical effects of antiepileptic drugs in newborns of chronically treated epileptic mothers.
Abstract : Epilepsia, 22 : 368, 1981

BOSSI L.
Newborns of epileptic mothers - a review of clinical and pharamcological findings in the perinatal and neonatal period.

BATTINO D., **BOSSI L.**, CANGER R., MARGSTAKLER E., MOLTENI B., ROSSI E., SPINAL S.
Coagulation function in newborns treated in utero with antiepileptic drugs.
Abstract : Epilepsia 22 : 367, 1981

LE TOUQUET - 1-4 October 1980
Colloque Neuroscience (DGRST, CNRS, INSERM)
MUNARI C., STOFFELS C., **BOSSI L.**, TALAIRACH J., LLOYD K.G., ROVEI V., WORMS P., MORSELLI P.L., BANCAUD J.
Aspects neuropharmacologiques et neurochimiques du cortex cérébral chez l'homme épileptique.
Abstracts, pp. 7-8

SANTA MARGHERITA LIGURE - November 1980
Riunione autunnale Società Italiana EEG e Neurofisiologia Clinica
MUNARI C., STOFFELS C., **BOSSI L.**, TALAIRACH J., ROVEI V., BANCAUD J., MORSELLI P.L.
Aspetti neurofarmacologici in pazienti con epilessia resistente alla terapia medica

ROME - November 1980
Riunione annuale Società Italiana Neurochirurgia

MUNARI C., TALAIRACH J., **BOSSI L.**, STOFFELS C., ROVEI V., BANCAUD J., MORSELLI P.L.
Concentrazioni cerebrali dei farmaci antiepilettici in pazienti con epilessia resistente ai trattamenti farmacologici

1981

PARIS - 8 March 1981
Société d'EEG et de Neurophysiologie Clinique de langue française
BOSSI L., MUNARI C., STOFFELS C., BONIS A., BACIA T., TALAIRACH J., BANCAUD J.
Manifestations somatomotrices dans les crises d'épilepsie d'origine temporale
Abstract : EEG Clin. Neurophysiol., 55 : 13, 1983

SERRE-CHEVALIER - 22-29 March 1981 (chairperson)
Méthodologie des essais cliniques en neurologie
BOSSI L.
Intérêt de la détermination des taux plasmatiques des médicaments au cours des essais cliniques.

PARIS - 27-30 April 1981
Fourth International meeting of pharmaceutical physicians
BOSSI L., HENRY J.F., VADROT M.
Methodological problems in the determination and evaluation of adverse events during the phases I, II and III of drug development

MARSEILLE - 4-5 May 1981
Xèmes journées de Méthodologie de la Recherche en Psychiatrie
BOSSI L., MORSELLI P.L.
Intérêt des études pharmacocinétiques et de la surveillance des niveaux plasmatiques des neuroleptiques en psychiatrie.

SEILLAC - 6-9 May 1981
Workshop on Neurotransmitters in epilepsy (WONIEP I) :

BOSSI L., ZIVKOVIC B., SCATTON B., MORSELLI P.L., MUNARI C., STOFFELS C, BANCAUD J.
Ventricular CSF concentrations of monoamine metabolites in epileptic patients
Abstracts

LLOYD K.G., MUNARI C., **BOSSI L.**, TALAIRACH J., MORSELLI P.L.
Biochemical evidence for the alterations of GABA-mediated synaptic transmission in human epileptic foci
Abstracts

AVIGNON - 11-15 May 1981
Vth International Symposium on Column liquid chromatography
SMERDJIAN ROUQUIER L, **BOSSI L.**, SCATTON B.

Concurrent determination of 5-hydroxytryptophan serotonin and 5-hydroxyindoleacetic acid in rat brain and human biological fluids by reversed-phase high performance liquid chromatography with electrochemical detection.
Abstracts.

PARIS - 3 June 1981
Société d'EEG et de Neurophysiologie Clinique de Langue Française
AVANZINI G., **BOSSI L.**, CARENINI L., FRANCESCHETTI S., PARINI C.
Evaluation électro-clinique de l'effet sur les myoclonies non post-anoxiques de substances supposées agir sur les neuromédiateurs.

SANTA FLAVIA (PALERMO) - 18-20 June 1981
Convegno Lega Italiana contro l'Epilessia
BOSSI L.
Epilessia, farmacoresistenza e sistema GABA : dati farmacologici e biochimici tissutali e liquorali nell'uomo.

KYOTO - 13-18 September 1981
International Meeting on EEG and Clinical Neurophysiology
MORSELLI P.L., **BOSSI L.**, MUNARI G.
Should EEG recordings be included in clinical trials of anticonvulsant drugs ?

KYOTO - 17-21 September 1981
XIIIth Epilepsy International Symposium :
(chaiperson of session « Neurotransmitters and other substances »)

MUNARI C., STOFFELS C., **BOSSI L.**, BRUNET P., BONIS A., BANCAUD J., TALAIRACH J.
Partial seizures with elementary or complex symptomatology : a valid classification for temporal lobe seizures ?
Abstracts, p. 61-62

STOFFELS C., MUNARI C., **BOSSI L.**, BRUNIE-LOZANO E., BONIS A., BANCAUD J., TALAIRACH J.
Seizures of the anterior cingular gyrus in man : a stereo-EEG study
Abstracts, p. 85-86

BOSSI L., MUNARI C., STOFFELS C., BONIS A., TALAIRACH J., BACIA T., BANCAUD J.
Somatomotor manifestations in temporal lobe seizures
Abstract

MORSELLI P.L., MUNARI C., **BOSSI L.**, STOFFELS C., BANCAUD J., TALAIRACH J., LLOYD K.G.
Alterations of GABA neuronal biochemistry in surgically resected epileptogenic areas in man
Abstracts, p. 88

BOSSI L., MUNARI C., STOFFELS C., BANCAUD J., TALAIRACH J., MORSELLI P.L.
Antiepileptic drugs concentrations in brain specimens from therapy resistant epileptic patients

Abstracts, p. 119

MARTINEZ-LAGE M., **BOSSI L.**, MORALES G., MARTINEZ-VILA E., POLANOS H.
A double-blind cross-over trial of Progabide versus placebo in severe epilepsy
Abstract

BOSSI L., ZIVKOVIC B., SCATTON B., DEDEK J., MUNARI C., STOFFELS C., BANCAUD J., TALAIRACH J., MORSELLI P.L.
Ventricular CSF concentrations of NA, DA, HVA, 5-HIAA, cAMP and cGMP in epileptic patients
Abstracts, p. 85-86

LONDON D.R., KANDEEL F., LOIZOU L.A., BUTT W.R., MORSELLI P.L., **BOSSI L.**, VAN LANDEGHEM V.
The endocrine effects of progabide in healthy male volunteers
Abstract

MUNARI C., STOFFELS C., **BOSSI L.**, BRUNET P., BONIS A., TALAIRACH J., BANCAUD J.
Automatic activities in temporal lobe seizures without involvement of temporal lobe structures
Abstracts, p. 63-64

MILANO - 23-24 October 1981
Idee, proposte e contributi per il piano sanitario regionale : epilessia
AVANZINI G., BATTINO D., BINELLI S., **BOSSI L.**, BRESCHI F., CACCAMO M.L., CANGER R., CEFALA A., COMO M.L., CROCI D., CUSI C., DE GIAMBATTISTA M., FERRARO G., FRANCESCHETTI S., LATIS G.O., MARINI A., MOISE A., NOLTENI B., PARDI G., PIFAROTTI G., SERENI F., SCHIRO G.P., SIMIONATO L. (Gruppo collaborativo milanese per lo studio dell'epilessia in gravidanza)
Gravidanza ed epilessia

HILTON HEAD ISLAND - 6-8 December 1981
Symposium on antiepileptic drugs in newborns, infants, children and adolescents
BOSSI L.
Fetal effects of anticonvulsants

1982

PERUGIA - May 1982
Réunion conjointe des ligues espagnoles, française et italienne contre l'épilepsie
MUNARI C., BONIS A., **BOSSI L.**, CHODKIEWICZ J.P., BRUNET P., SZIKLA G., TALAIRACH J., BANCAUD J.
Etude anatomo-electro-clinique de certaines épilepsies post-traumatiques graves chez l'adulte.

JERUSALEM - June 1982
CINP

BATHIEN N., RONDOT P., SEVESTRE P., FOURNIER V., **BOSSI L.**, MORSELLI P.L.
The effect of progabide, a specific GABA-ergic agonist on neuroleptic induced tardive dyskinesia. Results of an open pilot and a double blind placebo trial.
Poster.

LONDON - August 1982
XIV Epilepsy International Symposium :

BOSSI L., BIANCHETTI G., CAQUERET H., MORSELLI P.L., GUYOT M., LOISEAU P.
Preliminary observations on the possible influence of progabide on the bioavailability of associated AEDs in epileptic patients
Abstracts

BOSSI L., BIANCHETTI G., GUYOT M., CAQUERET H., LOISEAU P., MORSELLI P.L.
Preliminary observations on the possible interactions between CBZ and progabide in healthy volunteers
Abstracts

MUNARI G., BRUNET P., CHODKIEWICZ J.P., TALAIRACH J., **BOSSI L.**, BANCAUD J.
Stereo-EEG study of severe post-traumatic epilepsies
Abstracts

PHOENIX (ARIZONA) - 10-16 November 1982
Joint annual meeting, American EEG Society, American Epilepsy Society, and WOMAD I (Workshop on the metabolism of antiepileptic drugs)
MORSELLI P.L., BURKE J.T., FERRANDEZ B., PADOVANI P., BIANCHETTI G. , **BOSSI L.**, GOMENI R., THENOT J.P., THIERCELIN J.P.
Pharmacokinetic profile of progabide in 5 animals species and man
Abstract

1983

TORINO - 19 March 1983
Simposio su « Attualità e prospettive in tema di terapia dell'epilessia e monitoraggio dei farmaci
MORSELLI P.L., **BOSSI** L.
Farmaci GABA agonisti come nuovi agenti antiepilettici

SAN ANTONIO (TEXAS) - April 1983
WONIEP II
BOSSI L., MORSELLI P.L.
Antiepileptic efficacy of GABA agonists in man
Abstract

9th INTERNATIONAL MEETING OF THE INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY, 1983
LLOYD K.G., MUNARI C., **BOSSI L.**, MORSELLI P.L.

Status of GABA ergic neurons in human epileptic foci, as defined by neurochemistry

ROME - 30 May-2 June 1983
Società Italiana di Neurologia, Società di EEG e Lega contro l'Epilessia
BOSSI L.
Sistema GABA e farmacoresistenza

WASHINGTON - 26-30 September 1983
15th Epilepsy International Symposium :

WALLACE S.J., **BOSSI L.**
Response-conditional two-period crossover trial of progabide versus ethosuximide in absence seizures
Abstracts, p 245

WEBER M., VESPIGNANI H., REMY M.L., REGNIER F., **BOSSI L.**
A double-blind crossover trial of progabide versus placebo in therapy resistant epilepsies
Abstracts, p 348

BOSSI L., BEAUSSART M., BENOIT, BROGLIN D., CAMBIER J., CHATEL M., DEVILLE M.C., FAVEL P., GEETS, GOAS J.Y., LOISEAU P., LOUETTE
Long term treatment with progabide in severe epileptic patients : preliminary results of a multicenter trial
Abstracts, p 344

MORSELLI P.L., LOISEAU P., MARTINEZ-LAGE M., **BOSSI L.**
Long term treatment with progabide in resistant epilepsies
Abstracts, p 167

LOISEAU P., COURJON J., KURTZ D., GAREL S., MICHELETTI G., VERCELLETTO P., **BOSSI L.**
Multicenter comparative trial of progabide versus sodium valproate in therapy resistant epilepsies
Abstracts, p 345

LLOYD K.G., MUNARI C., **BOSSI L.**, MORSELLI P.L.
Biochemistry of hyman epileptic brain tissue
Abstracts, p 84

BATTINO D., BINELLI S., **BOSSI L.**, CANGER R., COMO M.L., CUSI C., DE GIANBATTISTA M., PARDI G., AVANZINI G.
Monitoring of antiepileptic drugs, estrogen, estriol placental lactogen and progesterone concentrations in pregnant epileptics
Abstracts, p 58

BOSSI L., BATTINO D., CACCAMO M.L., CUSI C., LATIS G., MOISE A., MOLTENI B., BRESCHI F.
Risk of malformations in newborns of epileptic mothers. Updated results of the Milan Collaborative study

Abstracts, p 234

BATTINO D., BINELLI I., CACCAMO M.L., CROCI D., CUSI C., **BOSSI L.**
Anthropometric data in 100 newborns of epileptic mothers : relationship to antiepileptic drugs
Abstracts, p 272

BOSSI L., BATTINO D., BINELLI S., CUSI C., CACCAMO M.L., LATIS G.
Side effects of AEDs in 100 newborns of epileptic mothers-relationship to drug type and blood concentrations
Abstracts, p 274

1984

PARIS - 29 February-2 March 1984 (chief organizer & editor)
Epilepsy and Gaba Receptor agonists : Basic and Therapeutic Research. International Symposium :

LLOYD K.G., **BOSSI L.**, MORSELLI P.L., MUNARI C., ROUGIER M., LOISEAU P.
Biochemical evidence for the dysfunction of GABA synapses in human epilepsy

DULAC O., **BOSSI L.**, REGNIER F., POULAIN D., BATTIN J., DANDELOT J.B., ATHUIS M.
Long term open trial of progabide in epileptic children

BOSSI L., BEAUSSART M., COURJON J., FOURNIER V., GAREL S., KURTZ D., MARESCAUX C., MEAULLE F., MICHELLETTI G., OROFIAMMA B., VERCELLETTO P., WEISS E., LOISEAU P.
Multicentric study of progabide versus sodium valproate in epilepsy

COQUELIN J.P., KRALL R., **BOSSI L.**, MUSCH B., MORSELLI P.L.
Progabide safety

BOSTON - 8-14 April 1984
American Academy of Neurology
DANDELOT J.B., **BOSSI L.**, POULAIN D., MUSCH B., MORSELLI P.L.
Progabide monotherapy in previously untreated epileptic patients
Abstracts : Neurology, Vol 34, Number 3, suppl. 1 : 6, p 266

LES EMBLIEZ - 15-19 May 1984
GESA XIV (Groupe d'étude Structure-Activité)
BOSSI L.
Agonistes des récepteurs GABA et épilepsie : le profil antiépileptique du progabide chez l'homme
Abstract

FLORENCE - 20-23 June 1984
14th CINP Congress :

BOSSI L.

Progabide in childhood epilepsy
Abstract

LOISEAU P., **BOSSI L.**, MORSELLI P.L.
Clinical experience with GABA agonists
Abstract

FOURNIER V., SEVESTRE P., ZIEGLER M., BATHIEN N., **BOSSI L.**, MUSCH B., MORSELLI P.L.,
Results of an open, dose-ranging trial with progabide in neuroleptic induced tardive dyskinesia
Abstract, p. 1027

ZIEGLER M., FOURNIER V., **BOSSI L.**, MUSCH B., RONDOT P., MORSELLI P.L.
The effects of progabide on the « on-off » phenomena of long term levodopa treated parkinsonians : results of a double blind trial of progabide versus placebo
Abstract, p. 1063

PARIS - 8 August 1984
GABA et maladies affectives : approche expérimentale et clinique. Symposium International
MUSCETTOLA G., CASIELLO M., GIANNINI C., **BOSSI L.**
Open pilot study of progabide in depression

PARIS - 3 December 1984
Réunion de la Ligue Française Contre l'Epilepsie : « Epilepsie et tératogénèse »
BOSSI L.
Epilepsie et tératogénèse, Synthèse et Conclusion pratique

PARIS - 11-14 December 1984
Congrès International du Traitement du Signal en électrophysiologie expérimentale et clinique du système nerveux central
MUSCH B., **BOSSI L.**
Predictivity of clinical pharmacology studies

1985

BUENOS AIRES - 14-16 March 1985
International Symposium on Extrapyramidal Diseases
BOSSI L.
GABA and movement disorders

ROME - 18-21 April 1985
3rd European Workshop on Clinical Neuropharmacology :

MUSCH B., **BOSSI L.**, FOURNIER V., MORSELLI P.L.
GABA-agonists in the treatment of human dyskinesia

BOSSI L., MUSCH B., FOURNIER V., PIERROT-DESSEILLIGNY E., BUSSEL B., HELD J.P., MORSELLI P.L.

Antispastic effect of progabide in man

NEW YORK - 9-12 June 1985
VIIIth International Symposium on Parkinson's Disease
ZIEGLER M., FOURNIER V., **BOSSI L.**, MUSCH B., MORSELLI P.L., RONDOT P.
Therapeutic response to progabide in neuroleptic and levodopa dyskinesias

HAMBURG - 6-9 September 1985 (chairperson)
16th Epilepsy International Congress :

MUSCH B., CAMBIER J., LOISEAU P., FOURNIER V., **BOSSI L.**, BEAUSSART M., BENOIT C., CHATEL M., DEVILLE M.C., FAVEL P., FERRIERE G., GEETS W., GOAS J.Y., KULAKOWSKI S., LOUETTE N., MARTINEZ-LAGE M., REMY C.
Open long term multicenter trial with progabide in epileptic patients

DULAC O., **BOSSI L.**, ARTHUIS M.
Long term open trial of progabide in epileptic children

BOSSI L., DANDELOT J.B., POULAIN D., MORSELLI P.L.
Progabide monotherapy in previously untreated epileptic patients

PESTRE M., **BOSSI L.**, LOISEAU P.
Acute effects of single dose administration of SL 78 424 on human photosensitivity

BOSSI L., POULAIN D.
Progabide safety after massive overdose in 4 subjects

BOSSI L., MORSELLI P.L.
Fetal effects of progabide

MORSELLI P.L., BENASSI E., BESIO G., BIANCHETTI G., MUSCH B., **BOSSI L.**, LOEB C.
Blood levels of progabide (PGB) and its active metabolite (PGA) in epileptic patients : relationship to the therapeutic outcome

PALMINTERI R., L'HERITIER C., **BOSSI L.**
Progabide and liver function tests

SOVERATO (CATANZARO) - 17-19 September 1985
Third Workshop on neurotransmitters in epilepsy (WONIEP)
BOSSI L., MORSELLI P.L.
Antiepileptic efficacy of GABA receptor agonists

VILLARD DE LANS (GRENOBLE) - 9-11 October 1985
BOSSI L., BRUNOD R., FOURNIER V., MORSELLI P.L., MUSCH B., RONDOT P., SEVESTRE P., ZIEGLER M.
Neurotransmitter interactions in the basal ganglia
Abstract

HILTON HEAD ISLAND - 18-19 November 1985
Workshop on problems in clinical development of antiepileptic drugs
BOSSI L.
Design of clinical trials in naive patients

1986

PAMPLONA - 10-13 June 1986 (Member of the International Advisory Board)
4th European Workshop on Clinical Neuropharmacology

1987

WASHINGTON - 30 May-2 June 1987
Regulatory Affairs Professionals Society, 11th International Meeting
BOSSI L.
Implementation and monitoring of clinical trials in Europe

1990

MADRID - 25-27 January 1990
International Symposium
Ramon y Cajal - past, present and future
BOSSI L.
Three key-words for the next decade

PARIS - 12 June 1990
La Cité des Sciences, Colloque Science, Culture, Institutions
BOSSI L.
Science, Culture, Institutions

ROME - 10-14 July 1990 (poster)
European Conference on Parkinson's Disease and Extrapyramidal Disorders
BOSSI L., GUILLOU G.B., BIANCHETTI A., LEFEVRE A., VIDAILLET M., BONNET A.M., GROUIN J.M., RAKOTONDRAINIBE S., MEYRIGNAC Ch.
Phosphatidylserine as an add-on therapy in L-Dopa treated parkinsonian patients

PRAGLIA ABBEY (PADOVA) - October 1990 (invited participant)
International School of Neuroscience, 2nd course, Developmental neurobiology

1991

BORDEAUX - 26-27 April 1991
Functional recovery in the central nervous system
BOSSI L.
Degeneration and regeneration of the nervous system : new pharmacological approaches

1992

LAUSANNE (SWITZERLAND) - 25-27 June 1992
Second European Stroke Conference
ORGOGOZO J.M., CAUSSANEL J.P., WOIMANT F., GROUIN J.M., GUILLOU G.B., **BOSSI L.**
FOR THE I.S.G. STUDY GROUP
Outcome of MCA infarction with severe brain oedema. A prospective study.

YOKOHAMA (JAPAN) - 26-31 July 1992
Vth World Conference on Clinical Pharmacology and Therapeutics
GUILLOU G.B., BIANCHETTI A., GUILLAUME M., DOUIN M.J., THEBAULT J.J., **BOSSI L.**
Pharmacokinetics of two doses of CRONASSIAL (40 and 100 mg) after single and repeated I.M. administration to healthy volunteers

BIANCHETTI A., GUILLOU G.B., GUILLAUME M., DOUIN M.J., MIGNOT A., **BOSSI L.**
Pharmacokinetics of SYGEN (100 mg) after single I.V., I.M., S.C. administration to healthy volunteers

IBIZA (SPAIN) - 15-17 October 1992 (invited speaker)
Valencian Society of Neurology
BOSSI L.
Utilidad del GM1 en patologia vascular cerebral

1993

NEW-YORK - 25 April-1st May 1993
American Academy of Neurology, 45th Annual Meeting :

BOSSI L., GROUIN J.M., GUILLOU G.B., PRIVAT A., TADIE M.
New approaches to the design of clinical trials in acute spinal cord injury
Abstract : Neurology

BOSSI L.
Cesare Lombroso : the born criminal and epilepsy
Abstract : Neurology

VANCOUVER - 5-10 September 1993 (poster)
XVth World Congress of Neurology
BOSSI L.
An iconographic approach to the clinical picture of hysteria in the work of J.M. Charcot and P. Richer
Abstract

1998

INGOLSTADT, (Deutsches Medizinhistorisches Museum), 14 February 1998 (invited speaker)
Münchner Medizinische Wochenschrift-Arzneimittelpreis
L. BOSSI
Lange Tradition und wichtige Zukunftsoption bei Sanofi

MARNES LA COQUETTE, November 3, 1998 (invited speaker)
Les neuropathies autoimmunes
L. BOSSI
Perspectives thérapeutiques des neuropathies périphériques

PARIS, 5-7 November 1998 (invited speaker)
Alzheimer's disease : the therapeutic era
L.BOSSI, Disease-modifying treatment for Alzheimer's disease : the neurotrophic approach.
Abstract : Alzheimer's reports, Vol.1, Suppl.1, November 1998, S29

1999

MONTPELLIER, 17 March 1999 (invited speaker)
La semaine du cerveau
L. BOSSI
Stratégies de recherche de nouveaux médicaments

2000

PARIS, 4 October 2000 (invited speaker)
Les effets secondaires des anticancéreux
L. BOSSI
Neurotoxicité des dérivés du platine

2001

TILLBURG (Hollande) 4 February 2001 (invited speaker)
Nexus conference 2001
The quest of life: Love and death
L.BOSSI
The future of death

2002

BUDAPEST (Hungary) , March 22-23, 2002 (invited speaker)
Eloxatin international meeting
L. BOSSI
Managing neurosensory symptoms